{"Title": ["IWD's Holdings Could Mean 20% Gain Potential", "First Week of July 17th Options Trading For Alkermes (ALKS)", "Alkermes PLC (ALKS) Q1 2020 Earnings Call Transcript", "Alkermes Withdraws 2020 Guidance - Quick Facts", "Alkermes plc Q1 adjusted earnings Beat Estimates", "Alkermes Q1 20 Earnings Conference Call At 8:00 AM ET", "Thursday's ETF Movers: REM, FBT", "Alkermes To Present At Cowen And Co Health Care Conference; Webcast At 3:30 PM", "IWD's Holdings Could Mean 20% Gain Potential", "5-Stock-Sampler Review-a-Palooza", "Analysts Predict 19% Upside For FBT", "Alkermes PLC (ALKS) Q4 2019 Earnings Call Transcript", "Alkermes Issues FY20 Outlook In Line With Estimates - Quick Facts", "Alkermes plc Q4 adjusted earnings Beat Estimates", "Alkermes Q4 19 Earnings Conference Call At 8:00 AM ET", "Here's Why Alkermes Jumped Almost 11% Today", "Bullish Two Hundred Day Moving Average Cross - ALKS", "Interesting ALKS Put And Call Options For March 20th", "Alkermes To Present At J.P. Morgan Healthcare Conference; Webcast At 12:00 PM ET", "Analysts See 12% Upside For FTXH", "Interesting ALKS Put And Call Options For August 2020", "Analysts See 11% Gains Ahead For FTXH", "Why Is Alkermes Stock Down 30% So Far This Year?", "Why Is Alkermes Stock Down 30% So Far This Year?", "Alkermes Becomes Oversold (ALKS)", "Analysts Predict 14% Gains Ahead For The Holdings of EQAL", "Alkermes Says FDA Approves Vumerity For Multiple Sclerosis", "Alkermes PLC (ALKS) Q3 2019 Earnings Call Transcript", "Alkermes Raises FY19 Adj. Earnings Outlook; To Incur Q4 Charge - Quick Facts", "Alkermes plc Q3 adjusted earnings Beat Estimates", "Alkermes Q3 19 Earnings Conference Call At 8:00 AM ET", "Better Buy: Biogen vs. Amgen", "Alkermes To Acquire Rodin Therapeutics - Quick Facts", "Analysts Predict 14% Gains Ahead For The Holdings of EQAL", "Alkermes Says FDA Approves Vumerity For Multiple Sclerosis", "ALKS Settles Patent Suit, Once-Monthly Contraceptive In The Works, NBIX On Watch", "Alkermes Bounces Back -- but Not Enough", "Alkermes PLC (ALKS) Q2 2019 Earnings Call Transcript", "Alkermes plc Q2 adjusted earnings Beat Estimates", "First Week of October 18th Options Trading For Alkermes (ALKS)", "Alkermes Becomes Oversold (ALKS)", "Alkermes is Now Oversold (ALKS)", "First Week of ALKS June 21st Options Trading", "Analysts Expect 14% Gains Ahead For The Holdings of RXL", "Alkermes Looks Ahead to Growth", "Alkermes PLC (ALKS) Q1 2019 Earnings Call Transcript", "Health Care Sector Update for 04/25/2019: WST,BMY,EXEL,ALKS", "Biogen Raises Guidance as It Looks to the Pipeline for Growth", "Here's Why Shares of Alkermes Sank Today", "Health Care Sector Update for 04/25/2019: ALKS,BMY,EXEL", "Alkermes plc Q1 adjusted earnings Beat Estimates", "Alkermes Reports Positive Data From Schizophrenia Study", "Alkermes says long-acting drugs could help schizophrenics stay on medication longer", "Long-acting injectable drugs could help schizophrenics stay on medication longer", "Alkermes Announces Positive Topline Results From ALPINE Study", "Biogen Looks to 23 Clinical Programs for Growth", "Recro Pharma Falls as FDA Denies Approval to Pain Candidate", "Alkermes Focuses on Pipeline, Depends on Partners for Funds", "Is Biogen a Bad-News Buy Now?", "Why Is Alkermes (ALKS) Up 4.7% Since Last Earnings Report?", "Allergan's Depression Candidate Fails in Studies, Stock Down", "Biotech Stock Roundup: ONCE, CMTA Soar on Merger News, Other Pipeline Updates", "Alkermes' (ALKS) and Biogen's NDA for BIIB098 Accepted by FDA", "Analysts Predict 10% Gains Ahead For VUG", "Biotech Stock Roundup: ICPT Strong on NASH Drug Data, Collaborations & More", "Alkermes Breaks $1 Billion", "We Did The Math EQWM Can Go To $55", "Consumer Sector Update for 02/19/2019: MOR,CNDT,ICPT,CLVS,ALKS", "Health Care Sector Update for 02/19/2019: CNDT,ICPT,CLVS,ALKS", "Tuesday's ETF with Unusual Volume: PBE", "Alkermes (ALKS) Q4 Earnings & Revenues Surpass Estimates", "The Zacks Analyst Blog Highlights: Intercept, Gilead, Vertex, Alkermes and Clovis", "Alkermes Plc (ALKS) Q4 2018 Earnings Conference Call Transcript", "The Zacks Analyst Blog Highlights: Gilead, Vertex, Celgene, Alkermes and AVEO", "Analysts Estimate Alkermes (ALKS) to Report a Decline in Earnings: What to Look Out for", "Biotech Stock Roundup: Celgene Tops in Q4, Gilead Disappoints, ALKS & AVEO Sink", "Notable Wednesday Option Activity: ALKS, DMRC, INGN", "Alkermes Sinks as FDA Refuses to Approve Depression Drug", "FDA declines to approve Alkermes opioid-based depression drug", "Alkermes (ALKS) Q4 Earnings and Revenues Beat Estimates", "What Makes Alkermes (ALKS) a New Buy Stock", "Surprising Analyst 12-Month Target For IWP", "CBM or ALKS: Which Is the Better Value Stock Right Now?", "Biogen Begins Improved Dosing Regimen on Tysabri in Phase III", "4 of the Fastest Growing Biotech Stocks in 2019", "Biotech Stocks Facing FDA Decision In January 2019", "Relative Strength Alert For Alkermes", "Biogen Looks to 2020", "What Makes Alkermes (ALKS) a New Buy Stock", "Alkermes Submits NDA For Diroximel Fumarate - Quick Facts", "Health Care Sector Update for 11/29/2018: ALKS,EYPT,JAZZ", "Health Care Sector Update for 11/29/2018: TNXP, ONCY, EYPT, ALKS", "Noteworthy Thursday Option Activity: ALKS, CDXS, SPLK", "Health Care Sector Update for 11/29/2018: ONCY,EYPT,ALKS", "Alkermes (ALKS) Down 14.2% Since Last Earnings Report: Can It Rebound?", "Alkermes, Biogen Submit NDA to FDA for Multiple Sclerosis Drug", "Just How Bad Is Alkermes' Depression Drug Setback?", "Noteworthy Friday Option Activity: AMBA, ABUS, ALKS", "Jazz Pharma (JAZZ) Beats on Q3 Earnings, Lowers Sales View", "Why Alkermes' Depression Drug Stumbled, and How Illumina Plans to Profit From M&A", "Noteworthy Thursday Option Activity: TREE, LGIH, ALKS", "Notable Wednesday Option Activity: ALKS, FANG, ERI", "Sum Up The Parts: SIZE Could Be Worth $95", "Alkermes (ALKS) Exceeds Q3 Earnings Estimates, Raises Outlook", "Alkermes (ALKS) Beats Q3 Earnings and Revenue Estimates", "Alkermes PLC (ALKS) Q3 2018 Earnings Conference Call Transcript", "Alkermes Boasts Strong Portfolio and Impressive Pipeline", "EBS or ALKS: Which Is the Better Value Stock Right Now?", "FDA Sets Action Date for Recro's Pain Management Candidate", "VistaGen Up on Fast Track Designation to Pain Candidate", "Alkermes Makes Financial Progress as Its Pipeline Moves Forward", "Are Options Traders Betting on a Big Move in Alkermes (ALKS) Stock?", "Alkermes Expands Study to Evaluate ALKS 4230-Keytruda Combo", "Relative Strength Alert For Alkermes", "Notable Tuesday Option Activity: ALKS, NCLH, EHTH", "Collaborations Help Alkermes Flip to Profitability", "What's in Store for Universal Health's (UHS) Q2 Earnings?", "What's in the Cards for HCA Healthcare (HCA) in Q2 Earnings?", "Allergan Eyes Vraylar Label Expansion, FDA Accepts sNDA", "Company News For Jul 3, 2018", "Alkermes' Aristada Initio Approved by FDA for Schizophrenia", "Morning Movers: Las Vegas Sands Tumbles, Tesla Jumps, Alkermes Soars", "Oversold Conditions For Alkermes (ALKS)", "Why Alkermes Tumbled 15% Today", "Why Stamps.com, iQiyi, and Alkermes Slumped Today", "First Week of ALKS February 2019 Options Trading", "Is a Beat in the Cards for Centene (CNC) in Q2 Earnings?", "Health Care Sector Update for 06/06/2018: ITCI,CLRB,ALKS,BIIB", "Analysts Forecast 12% Upside For EQWM", "Key FDA Events in June Investors Need to Watch Out For", "The Zacks Analyst Blog Highlights: Seagate, Grafton, Ingersoll-Rand and Alkermes", "Notable Friday Option Activity: SGMS, CSX, ALKS", "4 Top Stocks to Buy as Irish Economy Gathers Steam", "4 Top Stocks to Buy As Irish Economy Gathers Steam", "Health Care Sector Update for 06/06/2018: ENTA,ITCI,CLRB,ALKS,BIIB", "Alkermes (ALKS) Reports Wider-Than-Expected Loss in Q1", "Alkermes (ALKS) Q1 2018 Earnings Conference Call Transcript", "BioMarin (BMRN) Q1 Earnings Lower Than Expected, Sales Beat", "After a Bumpy Ride, Alkermes Confirms That It's Back on Track", "Interesting ALKS Put And Call Options For June 15th", "Is Alkermes' Promising Depression Drug Back On Track?", "Johnson & Johnson's First-Quarter 2018 Earnings Review", "Analysts Anticipate VV To Hit $136", "Alkermes Rallies as FDA Accepts NDA for Depression Drug", "Mid-Day Market Update: Crude Oil Down Over 1%; Eldorado Resorts Shares Surge", "Is It Time to Give Up on Alkermes?", "Mid-Morning Market Update: Markets Open Higher; Bank of America Earnings Top Estimates", "Morning Movers: Bank of America Gains on Earnings; Costco Rises on Upgrade", "Health Care Sector Update for 04/16/2018: ALKS, CLDX, APRI", "Biotech Stock Roundup: ALKS Up, CLDX Down, ALXN to Acquire Wilson Therapeutics", "Health Care Sector Update for 04/16/2018: CLDX,ALKS,APRI", "Alkermes Has Some Decisions to Make", "Will Shire Be Bought Out?", "5 Healthcare Stocks To Buy Today", "FDA Refuses Alkermes Depression Drug Review: 4 Stocks in Focus", "Allergan's Vraylar Meets Endpoints in Bipolar I Phase III", "Biotech Stock Roundup: EDGE Falls, ALKS Down, FDA OK's AMGN Drug Label Expansion", "Health Care Sector Update for 04/16/2018: SHPS,CLDX,ALKS,APRI", "Company News For April 3, 2018", "Alkermes Sinks as FDA Refuses Depression Drug Review", "Alkermes Enters Oversold Territory (ALKS)", "Monday's ETF with Unusual Volume: EQAL", "Monday's ETF Movers: GDXJ, FBT", "ALKS Crosses Below Key Moving Average Level", "Here's Why Alkermes plc and Intra-Cellular Therapies, Inc. Are Crashing Today", "Alkermes' Bad News Could Be Good News for Johnson & Johnson", "Morning Movers: Looks Like More Trouble Ahead", "Pre-Market Most Active for Apr 2, 2018 : TVIX, QQQ, ALKS, TSLA, WMT, MU, SQQQ, BABA, CHT, BAC, FIT, WBT", "What Happened in the Stock Market Today", "Noteworthy Monday Option Activity: TSLA, LFIN, ALKS", "Mid-Afternoon Market Update: Dow Falls Over 500 Points; Crude Oil Down 2.5%", "SPDR S&P Biotech ETF Experiences Big Inflow", "Commit To Purchase Alkermes At $45, Earn 11.5% Annualized Using Options", "Mid-Morning Market Update: Markets Open Lower; Cal-Maine Foods Posts Upbeat Sales", "Morning Movers: Looks Like More Trouble Ahead", "Health Care Sector Update for 03/01/2018: NVAX,ALKS,ATRA", "Better Buy: Biogen Inc. vs. Celgene Corporation", "3 Top Healthcare Stocks to Buy Right Now", "First Week of April 20th Options Trading For Alkermes (ALKS)", "Why Alkermes Is Sinking Today", "5 Stocks the World Really Needs Right Now: A 1-Year Performance Review", "3 Biotech Stocks That Soared This Week: Are They Buys?", "Notable Friday Option Activity: TRUE, BJRI, ALKS", "Stocks To Watch: Alkermes Sees Relative Strength Rating Rise To 85", "Alkermes Gets IBD Stock Rating Upgrade", "Alkermes (ALKS) Beats Q4 Earnings, Revenue Estimates", "Do Options Traders Know Something About Alkermes (ALKS) Stock We Don't?", "Here's Why Alkermes Spiked Today", "Alkermes Sets Itself Up for a \"Transformative\" 2018", "Shire (SHPG) to Report Q4 Earnings: What's in the Cards?", "Why Earnings Season Could Be Great for Alkermes (ALKS)", "Will Ocaliva Sales Dampen Intercept's (ICPT) Q4 Earnings?", "Agios Pharmaceuticals (AGIO) Q4 Earnings: What's in Store?", "Zoetis (ZTS) Warming Up to Q4 Earnings: What's in Store?", "Alkermes Breaks Below 200-Day Moving Average - Notable for ALKS", "5 Biotech Stocks Set to Trump Estimates This Earnings Season", "Pre-Market Earnings Report for February 14, 2018 : SHPG, HLT, DPS, IQV, TECK, TAP, CMS, WYN, BG, AER, IPG, ALKS", "Keryx (KERX) Warming Up to Q4 Earnings: What's in Store?", "Alkermes Reaches Analyst Target Price", "Is a Beat in Store for Alexion (ALXN) This Earnings Season?", "Strength Seen in Alkermes (ALKS): Stock Soars 8.7%", "This Explains Why Alkermes Plc Is Falling Today", "Why Wells Fargo, Advanced Micro Devices, and Alkermes Slumped Today", "Alkermes Submits NDA for Depression Candidate to the FDA", "Is a Beat in the Cards for ImmunoGen (IMGN) in Q4 Earnings?", "3 Pharma and Biotech Stocks to Watch Out for in 2018", "Spectrum Pharmaceuticals Up 134% in 6 Months: Here's Why", "3 Biotech Stocks Start Healthy in \u201918: Will the Rally Last?", "BlackRock, Pier One Imports, Alkermes, Vertex Pharmaceuticals and Agenus highlighted as Zacks Bull and Bear of the Day", "3 Biotech Stocks Start Healthy in '18: Will the Rally Last?", "3 Pharma and Biotech Stocks to Watch Out for in 2018", "Health Care Sector Update for 01/10/2018: JNJ,ALKS,ADVL,APHN", "3 Biotech Stocks to Buy for 2018", "Allergan's Vraylar Positive for Bipolar Disease in Phase III", "Surging Earnings Estimates Signal Good News for Alkermes (ALKS)", "Biotech Stock Roundup: Regeneron Down on Eylea Data, Biogen-Alkermes in MS Deal", "Biogen Acquires Worldwide License for Alkermes' MS Candidate (revised)", "Biogen Acquires Worldwide License for Alkermes' MS Candidate", "Why Is Alkermes (ALKS) Down 8.3% Since the Last Earnings Report?", "Is Biogen's Multiple Sclerosis Franchise Getting A New Lease On Life?", "Health Care Sector Update for 01/10/2018: APHB,ADVL,ALKS", "Biogen Inc. Buys Its Way Out of Competition", "Allergan's Vraylar Gets FDA Nod for Maintenance Therapy", "Alkermes (ALKS) Beats Q3 Earnings Estimates, Cuts Sales View", "Alkermes (ALKS) in Focus: Stock Moves 11.1% Higher", "The Clear Reason Alkermes Plc's Shares Jumped by as Much as 12%", "Alkermes Reports Mixed Results, Updates Guidance", "Allergan's (AGN) Vraylar Gets RTF From FDA, New Data for CVC", "Interesting ALKS Put And Call Options For January 2018", "Alkermes' ARISTADA Shows Better Results to Treat Schizophrenia", "Alkermes is Now Oversold (ALKS)", "Biotech Stock Roundup: EU Label Expansion for Alexion, BIIB Facing Drug Price Probe", "Alkermes Initiates Rolling Submission of Depression Drug", "Surprising Analyst 12-Month Target For IWP", "What You See, and What You Get: The Neurology of Perception", "Alkermes Enters Oversold Territory (ALKS)", "Implied BBH Analyst Target Price: $150", "Alkermes (ALKS) Q2 Loss Narrower than Expected, Sales Beat", "Alkermes Continues to Execute", "ALKS Crosses Below Key Moving Average Level", "We Did The Math FBT Can Go To $127", "Biotech Stock Roundup: Cara Plunges on Study Data, Regulatory Updates & More", "Alkermes Presents Phase III Data on Schizophrenia Candidate", "Minerva On Track to Initiate Phase III Schizophrenia Study", "3 Biotech Stocks for Enterprising Investors", "Alkermes Gets FDA Nod for Two Month Dose of Aristada", "Can Alkermes' Latest Approval Spark a Rally?", "Key FDA Events to Watch Out for in Jun 2017", "Alkermes (ALKS) Up 2.5% Since Earnings Report: Can It Continue?", "Woodford Investment Management LLP Buys Gilead Sciences Inc, Bioverativ Inc, Biogen Inc, Sells ...", "Analysts Forecast 12% Upside For BBH", "Alkermes' Revenue Jumps 22%", "Alkermes Commences Phase III Study for Schizophrenia Drug", "Meditor Group Ltd Buys Celldex Therapeutics, Sells VIVUS", "5 Drug Stocks for Your Portfolio this World Health Day", "3 Top Biotech Stocks to Buy in April", "Commit To Purchase Alkermes At $50, Earn 11.9% Annualized Using Options", "Alkermes Starts Phase III Study to Treat Multiple Sclerosis", "Allergan's (AGN) Vraylar sNDA Accepted for Review by FDA", "4 Things Alkermes Wants Investors to Know", "Alkermes (ALKS) Q1 Loss Wider than Expected, Sales Miss", "Alkermes (ALKS) Q4 Loss Narrower than Expectations, Sales Beat", "Pre-Market Earnings Report for February 15, 2017 : PEP, ADI, HLT, TECK, ETR, TRGP, BG, WYN, ALKS, HUN, FUN, ALE", "Why Sage Therapeutics Jumped Today", "Is Alkermes Poised for a Comeback in 2017?", "Naltrexone Showing More Potential in Drug Addiction Treatment Market", "Implied VUG Analyst Target Price: $126", "5 Drug Stocks to Avoid as Trump Vows to Lower Drug Prices", "Alkermes' Revenue Soars, Projects an Exciting Year Ahead", "Commit To Purchase Alkermes At $43, Earn 14.5% Annualized Using Options", "Alkermes PLC: Sales Rise, Losses Fall, and the Pipeline Moves Forward", "Alkermes (ALKS) Q3 Loss in Line, Sales Miss; '16 View Intact", "Drug Stocks to Watch for Earnings on Nov 2; AGN, ZTS & More", "Biotech Stock Roundup: Clinical Holds Hit Inovio & Aduro, Vertex Q3 Results Miss Estimates", "3 Stocks to Watch on Friday: Alkermes Plc (ALKS), Microsoft Corporation (MSFT) and Time Warner Inc (TWX)", "Alkermes Depression Candidate Positive in Phase III Study", "Acorda Stops Post-Stroke Development Program on Ampyra", "Health Care Sector Update for 10/21/2016: QTNT,ALKS,MWBO", "After Hours Most Active for Oct 20, 2016 : BAC, BBVA, MSFT, CA, CTSH, QQQ, ALKS, PYPL, VZ, PBR, KKR, PFE", "Alkermes Commences Metabolic Study on Schizophrenia Drug", "Intra-Cellular Reports Poor Phase III Schizophrenia Data", "Biotech Stock Roundup: Tobira Soars on Acquisition Deal, FDA Says Yes to Sarepta DMD Drug", "Moving Average Crossover Alert: Alkermes (ALKS)", "Alkermes (ALKS) Posts Narrower Q2 Loss, Ups 2016 Outlook", "Health Care Sector Update for 10/21/2016: MDRX,ALKS,MWBO", "XBI, JPXN: Big ETF Outflows", "SPDR S&P Biotech ETF Experiences Big Inflow", "Noteworthy ETF Outflows: XBI, IONS, ALKS, ICPT", "Look Under The Hood: JKH Has 11% Upside", "Alkermes Begins Phase I Study on Immuno-Oncology Drug", "Friday's ETF Movers: XBI, RHS", "XBI, MDVN, NBIX, ALKS: ETF Inflow Alert", "Alkermes (ALKS) Shares Cross Above 200 DMA", "Analysts Anticipate MTUM Will Reach $81", "Why Alkermes (ALKS) Stock Might be a Great Pick", "Alkermes Q4 Loss Narrower than Expected, Updates Pipeline", "Alkermes' ALKS 3831 in 2nd Phase III Study for Schizophrenia", "Commit To Purchase Alkermes At $23, Earn 13.6% Annualized Using Options", "Why Did Biotech Fall Off a Cliff in January?", "Sum Up The Pieces: PDP Could Be Worth $45", "Alkermes (ALKS) Reports Narrower-than-Expected Q1 Loss", "Alkermes Hit 52-Week Low on Unfavorable Phase III Data", "Thursday's ETF Movers: XOP, BBH", "Mid-Day Market Update: US Stocks Turn Higher; Plexus Shares Gain On Strong Results", "Here's Why Alkermes' Stock Is Tanking Today", "Mid-Morning Market Update: Markets Drop; Verizon Profit Tops Estimates", "US Stock Futures Move Into Black Closer to Open; Jobless Claims Rise More Than Expected", "Pre-Market Most Active for Jan 21, 2016 : TVIX, XIV, QQQ, ALKS, CBX, SMFG, UBS, ZFGN, SNY, BAC, NOK, SIRI", "Alkermes Initiates Early-Stage Study on Alzheimer's Drug", "Why Alkermes, Scholastic, and MGIC Investment Slumped Today", "Mid-Afternoon Market Update: Crude Oil Surges Over 4%; Alkermes Shares Slide Following Announcement of Failed Depression Drug Trial", "Arena, Boehringer Ingelheim Ink Deal, Schizophrenia in Focus", "5 Biotech Predictions for 2016", "Alkermes Upgraded to Hold on Encouraging Portfolio Update", "Alkermes Hits 52 Week High on Pipeline Update & Aristada", "Health Care Sector Update for 12/16/2015: MRNS, BIIB, ALKS", "US Equities Futures Point Slightly Lower as Europe Cling to Gains", "Why Alkermes, Scholastic, and MGIC Investment Slumped Today", "Mid-Afternoon Market Update: Crude Oil Surges Over 4%; Alkermes Shares Slide Following Announcement of Failed Depression Drug Trial", "Notable Two Hundred Day Moving Average Cross - ALKS", "Allergan/Gedeon's Vraylar Gets FDA Nod for Mental Disorders", "Intra-Cellular Up on Positive Data from Schizophrenia Study", "Biotech Stock Roundup: Acorda Gains on Patent Issues, Vital Crushed by Liver Data", "Alkermes' (ALKS) Aristada Review Date Postponed by FDA", "ALKS Makes Bullish Cross Above Critical Moving Average", "Alkermes' Reports Wider Q2 Loss, Increases Guidance - Analyst Blog", "Will McKesson (MCK) Keep the Earnings Streak Alive? - Analyst Blog", "Will Express Scripts (ESRX) Miss Earnings Estimates in Q2? - Analyst Blog", "Why I Think Alkermes Could Be a Top Performing Stock Ahead of 2016", "Midyear Report Card: Grading My Biotech Predictions for 2015", "First Week of ALKS February 2016 Options Trading", "Alkermes (ALKS) in Focus: Stock Rises 10.1% in Session - Tale of the Tape", "ALKS Crosses Below Key Moving Average Level", "3 Stocks Poised to Grow in the Schizophrenia Market - Analyst Blog", "First Week of ALKS July 17th Options Trading", "Alkermes' Q1 Loss Narrower than Expected, Maintains View - Analyst Blog", "ALKS Makes Notable Cross Below Critical Moving Average", "5 Biotech Stocks to Avoid After Monday's Slump - Analyst Blog", "First Week of ALKS June 19th Options Trading", "Midday Update: Stocks Holding On To Slim Gains Ahead of Upcoming Earnings Glut", "The Zacks Analyst Blog Highlights: Johnson & Johnson, AstraZeneca, ACADIA Pharmaceuticals, Actavis and Alkermes - Press Releases", "The Zacks Analyst Blog Highlights: Alkermes, Regulus, Juno Therapeutics, Targacept and Gilead - Press Releases", "Biotech Stock Roundup: Alkermes Drug Fares Well, Targacept Slides on Deal Termination - Analyst Blog", "Alkermes Reports Encouraging Data on Schizophrenia Drug - Analyst Blog", "Biogen/AbbVie's MS Drug Zinbryta Under Review in the EU - Analyst Blog", "Interesting ALKS Put And Call Options For November 20th", "Alkermes Streamlines Operations, Revises 2015 Guidance - Analyst Blog", "Health Care Sector Update for 04/13/2015: NEOT, AEZS, REPH", "A New Drug Could Halt Weight Gain in Patients Taking These Antipsychotics", "The Zacks Analyst Blog Highlights: Alkermes, Regulus, Juno Therapeutics, Targacept and Gilead - Press Releases", "Pre-Market Earnings Report for February 24, 2015 : HD, CMCSA, VRX, BMO, AMT, ECL, CMCSK, M, PLL, ALKS, WLK, UTHR", "Biotech Stock Roundup: Achillion Impresses with HCV Data, Regeneron 4Q Results Top Estimates - Analyst Blog", "Alkermes Reports Positive Data on Multiple Sclerosis Drug - Analyst Blog", "Tuesday's ETF Movers: VLUE, FBT", "Alkermes Intends to Add New Candidate to its Pipeline - Analyst Blog", "Alkermes plc (ALKS) in Focus: Stock Moves 6.6% Higher - Tale of the Tape", "5 Predictions for Biotechnology Stocks in 2015", "Cancel JPMorgan! Plenty of Pre-Conference Data and Deals to Digest", "Great News! An Exciting New Drug for Depression May Be on the Way", "Alkermes Soars on Positive Schizophrenia Drug Results - Analyst Blog", "Biotech Stock Roundup: Kite Flies High on Amgen Deal, Isis Soars on J&J Collaboration - Analyst Blog", "Alkermes Gains on Positive Depression Drug Study Data - Analyst Blog", "This Could Be Game-Changing News in the Battle Against Multiple Sclerosis", "First Week of ALKS August 2015 Options Trading", "Alkermes Starts Phase I Study on Schizophrenia Candidate - Analyst Blog", "3 Biotech ETFs Rally On Merger News", "First Week of January 2015 Options Trading For Alkermes (ALKS)", "Biotech: And Yet We've Just Begun...", "Alkermes Incurs Wider Q3 Loss but Revenues Grow Y/Y - Analyst Blog", "ALKS Crosses Above Key Moving Average Level", "Noteworthy ETF Outflows: VB, MDVN, COO, ALKS", "Alkermes Completes Enrolment for Phase II ALKS 3831 Study - Analyst Blog", "Sector Update: Health-Care Shares Flat Pre-Market", "Sector Update: Health Care", "Alkermes Gains on Aripiprazole Lauroxil NDA Submission - Analyst Blog", "Thursday's ETF Movers: BBH, GXC", "Alkermes Reports Loss in Q2 on Higher Costs, Revenues Up - Analyst Blog", "Biotech Stock Roundup: Gilead's Sovaldi & Biogen's Tecfidera Impressive Run Continues - Analyst Blog", "First Week of October 18th Options Trading For Alkermes (ALKS)", "Alkermes' Aripiprazole Lauroxil Looks Promising - Analyst Blog", "Sector Update: Healthcare", "Sector Update: Healthcare Shares Flat Pre-Market; Pfizer Teams with Cellectis on Immunotherapy", "Alkermes Progresses with its Late Stage Candidate - Analyst Blog", "Alkermes' Pipeline Holds Promise - Analyst Blog", "Wider-than-expected Loss at Alkermes, Revenues Slip - Analyst Blog", "Alkermes' Pipeline Development Impresses, Key Updates Ahead - Analyst Blog", "Sector Update: Healthcare Shares Mixed Pre-Market; WellPoint up 2% on Q1 Results", "Biotech Stock Roundup: MannKind PDUFA Date Pushed Out, Alkermes Impresses with Data - Analyst Blog", "Gilead Sciences (GILD) Falls: Stock Goes Down 7.3% - Tale of the Tape", "3 Top-Ranked Biotech Stocks on the Rebound - Analyst Blog", "Halozyme Study Under Clinical Hold - Analyst Blog", "ImmunoGen Up on Positive Pipeline Data - Analyst Blog", "Gilead Announces Encouraging Sovaldi Data - Analyst Blog", "Sector Update: Healthcare", "Positive Trial Data Lifts Alkermes - Analyst Blog", "Pharmacyclics Files sNDA - Analyst Blog", "Oncolytics Reports Additional Data on Reolysin - Analyst Blog", "Ambit's Oncology Drug in Phase III - Analyst Blog", "Seattle Genetics Earns Milestone Payment - Analyst Blog", "Halozyme Falls on Phase II Study Halt - Analyst Blog", "Bristol-Myers Seeks FDA Approval for HCV Candidates - Analyst Blog", "Biotech Stock Roundup: MannKind Soars on Panel Vote, Halozyme Plunges on Safety Concerns - Analyst Blog", "Positive Trial Data Lifts Alkermes - Analyst Blog", "RadNet Touches New 52-Week High - Analyst Blog", "Agios Pharmaceuticals (AGIO) Surges: Stock Moves 27.8% Higher - Tale of the Tape", "MannKind Slips on Afrezza Approval Delay - Analyst Blog", "Idenix Pharmaceuticals (IDIX) Jumps: Stock Up 12.4% - Tale of the Tape", "Puma Biotechnology (PBYI) in Focus: Stock Tumbles 18.3% - Tale of the Tape", "Sector Update: Healthcare Shares Higher Pre-Market; Alkermes up 11% on Phase 3 Trial Results", "FDA Target Date for Gilead's HCV Candidate - Analyst Blog", "Mid-Morning Market Update: Markets Mixed; A. Schulman Lifts Profit Outlook", "RadNet Touches New 52-Week High - Analyst Blog", "Agios Pharmaceuticals (AGIO) Surges: Stock Moves 27.8% Higher - Tale of the Tape", "MannKind Slips on Afrezza Approval Delay - Analyst Blog", "Pipeline Update from Idenix - Analyst Blog", "Healthcare Stocks Losing Ground Ahead of Closing Bell; Alkermes Up 3% on Positive Results for Schizophrenia Drug", "Sector Update: Healthcare", "Mid-Afternoon Market Update: Markets Recover Slightly as Coal Shows Strength", "Mid-Day Market Update: US Stocks Gain; Gigamon Shares Dip On Lower Forecast", "Amgen's Oncology Candidate Disappoints - Analyst Blog", "Response Genetics (RGDX) in Focus: Stock Up 18.3% - Tale of the Tape", "Weakness Seen in Kindred Biosciences (KIN): Stock Tumbles 9.0% - Tale of the Tape", "Glaxo and Amgen Terminate Agreement - Analyst Blog", "Acceleron Pharma (XLRN) Jumps: Stock Up 13.2% - Tale of the Tape", "Sector Update: Healthcare", "Celladon (CLDN) Jumps: Stock Up 5.9% - Tale of the Tape", "Momenta Pharmaceuticals Slumps: MNTA Falls 16.9% in Session - Tale of the Tape", "Exact Sciences (EXAS) Jumps: Stock Adds 10.2% in Session - Tale of the Tape", "Glaxo Presents Darapladib Data - Analyst Blog", "Idera Soars on Phase II Drug Data - Analyst Blog", "Alkermes Larger Than S&P 500 Component Joy Global", "Endocyte Prices New Offering at $21 Per Share - Analyst Blog", "Encouraging Results on Gilead's Sovaldi - Analyst Blog", "Gilead's HCV Candidate Under Review in the EU - Analyst Blog", "Insmed Incorporated saw its shares rise more than 7% in the session. - Tale of the Tape", "Encouraging Data on Pfizer Cholesterol Drug - Analyst Blog", "Integra LifeSciences Introduces Wound Matrix - Analyst Blog", "CVS Caremark Receives FEP contract - Analyst Blog", "BBH, ALKS, BMRN, ISIS: Large Outflows Detected at ETF", "China Cord Blood Corporation (CO) Soars: Stock Up 5.7% - Tale of the Tape", "FDA Nod for Biogen's Alprolix - Analyst Blog", "Gilead's HCV Candidate Under Review in the EU - Analyst Blog", "Avanir's AVP-825 under FDA Review - Analyst Blog", "Positive Data on Pfizer's Genotropin - Analyst Blog", "What Falling Estimates & Price Mean for Kythera (KYTH) - Tale of the Tape", "UCB to Return Tozadenant Rights - Analyst Blog", "Update on Forest Labs' Cariprazine - Analyst Blog", "Positive CHMP Opinion for Novo Nordisk's Drugs - Analyst Blog", "Exelixis' Cometriq Approved in the EU - Analyst Blog", "Insmed Down on Disappointing Arikayce Results - Analyst Blog", "Endocyte Surges on Vynfinit News - Analyst Blog", "Trial Protocol Submission Lifts Heat Biologics - Analyst Blog", "Sinovac Biotech (SVA) Soars: Stock Rises 17.1% - Tale of the Tape", "Strength Seen in ZIOPHARM Oncology (ZIOP): Stock Up 11.8% - Tale of the Tape", "Oncolytics Biotech (ONCY) Jumps: Stock Rises 5% - Tale of the Tape", "AVEO Pharmaceuticals (AVEO) Jumps: Stock Rises 7.2% - Tale of the Tape", "Glaxo's MAGE-A3 Candidate Disappoints Again - Analyst Blog", "Avanir Provides New Data - Analyst Blog", "Good News for Johnson & Johnson - Analyst Blog", "Positive Data on Novo Nordisk's N8-GP - Analyst Blog", "Prothena (PRTA) Jumps: Stock Rises 27.5% - Tale of the Tape", "Sequenom (SQNM) Soars: Stock Rises 6.4% - Tale of the Tape", "Why ANI Pharmaceuticals (ANIP) Has a Bright Short-Term Future? - Tale of the Tape", "Qiagen's QuantiFERON-TB Test Now in China - Analyst Blog", "OncoMed's Q4 Loss Narrows - Analyst Blog", "Intrexon Deal Update Overshadows Q4 Loss at Fibrocell - Analyst Blog", "Idenix Files Lawsuit vs. Gilead Again - Analyst Blog", "Novo Nordisk Extends Diabetes Operations - Analyst Blog", "BioLineRx Reports Narrower 2013 Loss - Analyst Blog", "Horizon Pharma (HZNP) Jumps: Stock Rises 5.6% - Tale of the Tape", "Narrower-Than-Expected Loss at Relypsa - Analyst Blog", "Genomic Health Unveils Oncotype DX Data - Analyst Blog", "Glaxo/Theravance Update on COPD Drugs - Analyst Blog", "Repros Provides Proellex Update - Analyst Blog", "Pipeline Update from BioDelivery Sciences - Analyst Blog", "Intercept Sees Weakness in Earnings Result - Analyst Blog", "Amgen Scores Again with PCSK9 Inhibitor - Analyst Blog", "Biogen to be added to S&P100 - Analyst Blog", "Update on Glaxo's Pipeline - Analyst Blog", "Five Prime Therapeutics (FPRX) Surges: Stock Moves 22.6% Higher - Tale of the Tape", "Glaxo/Theravance Update on COPD Drugs - Analyst Blog", "Revenues Decline at Discovery Labs in Q4, Shares Down - Analyst Blog", "Narrower-than-Expected Q4 Loss at Repros - Analyst Blog", "Vanda Pharmaceuticals (VNDA) Soars: Stock Adds 9.6% in Session - Tale of the Tape", "Insmed (INSM) Looks Good: Stock Adds 5.9% in Session - Tale of the Tape", "First Laminoplasty Implant at Integra - Analyst Blog", "AstraZeneca to Sell Cheshire Research Site - Analyst Blog", "Raptor Pharma Posts Wider-Than-Expected Q4 Loss - Analyst Blog", "Bright Outlook at Bayer - Analyst Blog", "Geron Plunges on FDA Clinical Hold - Analyst Blog", "Glaxo Strengthens Indian Presence - Analyst Blog", "Pipeline Update at BioLineRx - Analyst Blog", "Regado Rises on REG1 Fast Track Designation - Analyst Blog", "Alexion Lifts 2014 View, Shares Up - Analyst Blog", "Biogen Upgraded to Strong Buy - Analyst Blog", "Narrower Loss at Orexigen in Q4 - Analyst Blog", "Emergent Beats on Earnings & Revenues, Shares Up - Analyst Blog", "Additional Positive Data on Omeros Treatment - Analyst Blog", "NewLink Genetics' Shares Sink - Analyst Blog", "Why You Need to Pay Attention to Kamada (KMDA) Stock? - Tale of the Tape", "Alcobra Gains IND Clearance for MDX - Analyst Blog", "Pipeline Progress at Alkermes - Analyst Blog", "Rigel Rises on Narrower Q4 Loss - Analyst Blog", "Aegerion Pharmaceuticals (AEGR) Soars: Stock Rises 10.6% - Tale of the Tape", "Regulatory Update on Cubist Pharma's Tedizolid - Analyst Blog", "Update on Alexion's Soliris - Analyst Blog", "Narrower-than-Expected Q4 Loss at GTx - Analyst Blog", "Acorda Therapeutics (ACOR) Jumps: Stock Rises 7.5% - Tale of the Tape", "OvaScience (OVAS) in Focus: Stock Tanks 9.5% - Analyst Blog", "Narrower-than-Expected Loss at Dendreon Drives Shares Up - Analyst Blog", "Celldex Therapeutics (CLDX) in Focus: Stock Tumbles 10.1% - Tale of the Tape", "Osiris Misses on Q4 Earnings - Analyst Blog", "Actelion Gains on QIDP and Fast Track Status - Analyst Blog", "Update on Anacor's AN2728 - Analyst Blog", "Earnings Decline YoY at Alkermes - Analyst Blog", "Medivation Swings to Earnings in Q4 - Analyst Blog", "Zacks Rank #1 Additions for Friday - Tale of the Tape", "Interesting ALKS Put And Call Options For April 19th", "Isis Pharma Soars on Positive Data - Analyst Blog", "Isis Pharma Slips on Wider-Than-Expected Q4 Loss - Analyst Blog", "Actelion Gains on QIDP and Fast Track Status - Analyst Blog", "Notice of Allowance Received by Alkermes - Analyst Blog", "3 Rallying, Outperforming Stocks with High Employee Ratings", "Alkermes plc (ALKS): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report", "Pharma & Biotech Stock Outlook - Dec 2013 - Zacks Analyst Interviews", "Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook", "Vertex' Kalydeco Approved for an Additional Indication - Analyst Blog", "Strength Seen in Alkermes (ALKS): Stock Up 8.5% - Analyst Blog", "Alkermes' ALKS 5461 Encourages - Analyst Blog", "Alkermes' Pipeline Encourages - Analyst Blog", "Pipeline Progress at Alkermes - Analyst Blog", "Update on Alkermes' Portfolio - Analyst Blog", "Acorda Progresses with Pipeline - Analyst Blog", "Halozyme (HALO) in Focus: Stock Rises 6.9% - Analyst Blog", "Marginal Earnings Miss at Alkermes - Analyst Blog", "After Hours Most Active for Jul 3, 2013 : SIRI, QQQ, ITUB, VALE/P, ZTS, PBR, PBR/A, WFC, ALKS, WCRX, ZNGA, APOL", "Biogen Delays EU Launch of Tecfidera - Analyst Blog", "Amgen-Astellas Collaborate - Analyst Blog", "Encouraging Data from Alkermes - Analyst Blog", "Biogen Submits Plegridy BLA - Analyst Blog", "Alkermes Reports Earnings for Q4 - Analyst Blog", "Pre-Market Earnings Report for May 23, 2013 : TD, RL, HRL, DLTR, AAP, SIG, GME, PDCO, ALKS, BKE, TTC, AINV", "Earnings Beat at Alkermes - Analyst Blog", "After Hours Most Active for Jul 3, 2013 : SIRI, QQQ, ITUB, VALE/P, ZTS, PBR, PBR/A, WFC, ALKS, WCRX, ZNGA, APOL", "Biogen's Hemophilia BLA Accepted - Analyst Blog", "SGEN's Adcetris under FDA Review - Analyst Blog", "Cempra/Toyama Ink Deal - Analyst Blog", "Much Awaited Test Launch by Genomic - Analyst Blog", "Myriad Soars Higher on Celeb Clout - Analyst Blog", "Isis Gets $3.5M Milestone Payment - Analyst Blog", "Yet Another Acquisition for Bayer - Analyst Blog", "BioMarin Widens Loss, Maintains View - Analyst Blog", "Zacks Rank #1 Addition for Tuesday - Tale of the Tape", "Illumina Beats on Earnings, Revenue - Analyst Blog", "Pipeline Progress at Alkermes - Analyst Blog", "Mid-Day Market Update: Cirrus Logic Plunges On Weak Forecast, Atlas Energy Rises", "Mid-Morning Market Update: Markets Move Lower, Bank of America Posts Downbeat Q1 Profit", "Market Wrap for Wednesday, April 17: Stocks Plunge Again Along With Euro", "The Week Ahead: Full Slate of Economic Data; Earnings From Cisco, Wal-Mart and Deere", "Biotech Alkermes Poised To Swell On Pipeline Wins", "Alkermes Announces Restructuring Plan - Analyst Blog", "Setback for Amgen - Analyst Blog", "Royalty Pharma Eyes Elan Corp. - Analyst Blog", "Elan Updates Future Plans - Analyst Blog", "Symmetry Misses but Up Y-Y - Analyst Blog", "BioMarin Reports Wider Loss - Analyst Blog", "Mid-Afternoon Market Update: Markets Remain Down, ABIOMED Rises", "Savient to Promote Sobi's Kineret - Analyst Blog", "Celgene Plans $600M Share Buyback - Analyst Blog", "ALIOF Candidate Approved in Japan - Analyst Blog", "Positive Data from BMRN's PKU-016 - Analyst Blog", "Amgen Provides Long-Term Update - Analyst Blog", "Loss at MannKind Wider than Expected - Analyst Blog", "Affymetrix Links Up with DNA Link - Analyst Blog", "Zacks Rank #1 Addition for Friday - Tale of the Tape", "Data on Biogen Hemophilia Candidates - Analyst Blog", "Zacks Rank #1 Addition for Friday - Tale of the Tape", "Zacks Rank #1 Addition for Wednesday - Tale of the Tape", "Elan to Sell Remaining ALKS Stake - Analyst Blog", "Alkermes Turns to Profit, Ups View - Analyst Blog", "Affymetrix's 4Q EPS In Line - Analyst Blog", "Zacks Rank #1 Addition for Wednesday - Tale of the Tape", "Alkermes Plc Enters Oversold Territory - Tale of the Tape", "Data on Biogen Hemophilia Candidates - Analyst Blog", "Zacks Rank #1 Addition for Friday - Tale of the Tape", "Alkermes Maintains Fiscal 2013 View - Analyst Blog", "Positive Data on Alkermes Candidate - Analyst Blog", "Elan Hives Off Prothena - Analyst Blog", "Alkermes Reverts to Neutral - Analyst Blog", "Revenues Rise at Alkermes - Analyst Blog", "Arena Falters on Belviq EU Approval - Analyst Blog", "Alkermes Upped to Outperform - Analyst Blog", "Get Ready To Be Surprised This Earnings Season - Screen of the Week", "Alkermes' Debt Refinanced - Analyst Blog", "Zacks #1 Rank Additions for Friday - Tale of the Tape", "Back to Neutral on Alkermes - Analyst Blog", "Alkermes Writes New Prescription For Growth", "Elan to Split into Two Companies - Analyst Blog", "Alkermes, Plc (ALKS) - Bull of the Day", "Alkermes Plc Enters Oversold Territory - Tale of the Tape", "Solid Quarter at ALKS, View Backed - Analyst Blog", "Pre-Market Earnings Report for July 26, 2012 : MMM, PLD, AGCO, ABB, ALK, ALKS, DDD, ASPS, ACIW, AIXG, ALU, AMAG", "Alkermes, Plc (ALKS) - Bull of the Day", "Alkermes Upped to Outperform - Analyst Blog", "Zacks #1 Rank Additions for Monday - Tale of the Tape", "Pipeline Progress at Alkermes/JNJ - Analyst Blog", "A Company's First Profit Can Mean Big Gains for Investors - Screen of the Week", "Best Health Care Investor Edward Owens Buys One New Health Care Stock in First Quarter", "Elan Sells 76% Stake in Alkermes - Analyst Blog", "Risk-Reward Balanced at Alkermes - Analyst Blog", "The Zacks Analyst Blog Highlights: Charles Schwab, E*TRADE Financial, TD Ameritrade Holding, Amylin Pharmaceuticals and Alkermes plc - Press Releases", "Amylin's Bydureon Launches in the US - Analyst Blog", "Elan's 4Q Loss Wider Than Expected - Analyst Blog", "Novo Nordisk Posts Solid 4Q - Analyst Blog", "Revenues Skyrocket at Merged Alkermes - Analyst Blog", "Revenues Skyrocket at Merged Alkermes - Analyst Blog", "New Study for Alkermes' Vivitrol - Analyst Blog", "Zyprexa Pulls Down Lilly's 4Q Sales - Analyst Blog", "Third Time Lucky for Amylin's Bydureon - Analyst Blog", "Good News for Alkermes' Pipeline - Analyst Blog", "Pipeline Progress at Alkermes - Analyst Blog", "Pipeline Progress at Alkermes - Analyst Blog", "The Zacks Analyst Blog Highlights: Alkermes plc, Elan, Johnson & Johnson, Amylin Pharmaceuticals and Eli Lilly & Company - Press Releases", "Revenues Skyrocket at Merged Alkermes - Analyst Blog", "Mid-Day Update: Stocks Gain as Greece Worries Abate; Existing Home Sales Match Street, But Fall", "Stocks Gains as Greek Debt Crisis Eases, Home Sales In Line; Fed Meeting Ahead", "Stocks Accelerating Gains Despite Persistent Greek Debt Worries; Deal News Supports", "Mid-Day Update: Stocks Getting Lift from Deal News; Greece Worries Simmer", "Mid-Day Update: Stocks Firmer Following Data Deluge, Corporate Earnings", "Major Indexes in Positive Territory as Earnings Season Presses On; Fed Beige Book on Tap", "Greenback Rally? Here are the Stocks That Stand to Benefit", "Alkermes (ALKS) investor boosts call volume", "Bull looks for Alkermes to bounce", "Alkermes faces bearish strategy", "Bull extends position in Alkermes", "Mid-Day Update: Stocks In Strong Advance; Eyes Ahead to Fed's Beige Book"], "Elapsed Time": ["MAY 18, 2020", "MAY 15, 2020", "APR 29, 2020", "APR 29, 2020", "APR 29, 2020", "APR 29, 2020", "APR 9, 2020", "MAR 2, 2020", "MAY 18, 2020", "FEB 26, 2020", "FEB 14, 2020", "FEB 13, 2020", "FEB 13, 2020", "FEB 13, 2020", "FEB 13, 2020", "FEB 5, 2020", "FEB 26, 2020", "JAN 22, 2020", "JAN 15, 2020", "JAN 14, 2020", "DEC 24, 2019", "DEC 10, 2019", "NOV 26, 2019", "NOV 26, 2019", "JAN 24, 2020", "NOV 6, 2019", "OCT 30, 2019", "OCT 23, 2019", "OCT 23, 2019", "OCT 23, 2019", "OCT 23, 2019", "SEP 27, 2019", "NOV 18, 2019", "NOV 6, 2019", "OCT 30, 2019", "JUL 30, 2019", "JUL 26, 2019", "JUL 25, 2019", "JUL 25, 2019", "AUG 20, 2019", "JUN 6, 2019", "MAY 1, 2019", "APR 29, 2019", "APR 29, 2019", "APR 26, 2019", "APR 26, 2019", "APR 25, 2019", "JUL 24, 2019", "APR 25, 2019", "APR 25, 2019", "APR 25, 2019", "APR 10, 2019", "APR 9, 2019", "APR 9, 2019", "APR 9, 2019", "APR 25, 2019", "MAR 26, 2019", "MAR 21, 2019", "MAR 21, 2019", "MAR 16, 2019", "MAR 7, 2019", "FEB 27, 2019", "FEB 26, 2019", "MAR 28, 2019", "FEB 20, 2019", "FEB 19, 2019", "FEB 19, 2019", "FEB 19, 2019", "FEB 19, 2019", "FEB 19, 2019", "FEB 15, 2019", "FEB 21, 2019", "FEB 14, 2019", "FEB 7, 2019", "FEB 6, 2019", "FEB 6, 2019", "FEB 6, 2019", "FEB 4, 2019", "FEB 1, 2019", "FEB 14, 2019", "JAN 29, 2019", "JAN 17, 2019", "JAN 9, 2019", "JAN 4, 2019", "DEC 31, 2018", "DEC 24, 2018", "DEC 19, 2018", "JAN 30, 2019", "DEC 17, 2018", "DEC 17, 2018", "NOV 29, 2018", "NOV 29, 2018", "NOV 29, 2018", "NOV 29, 2018", "NOV 22, 2018", "DEC 18, 2018", "NOV 12, 2018", "NOV 9, 2018", "NOV 8, 2018", "NOV 8, 2018", "NOV 1, 2018", "OCT 24, 2018", "NOV 16, 2018", "OCT 23, 2018", "OCT 23, 2018", "OCT 23, 2018", "OCT 19, 2018", "OCT 18, 2018", "OCT 9, 2018", "OCT 4, 2018", "OCT 24, 2018", "SEP 19, 2018", "SEP 11, 2018", "SEP 7, 2018", "AUG 14, 2018", "JUL 27, 2018", "JUL 20, 2018", "JUL 20, 2018", "SEP 27, 2018", "JUL 3, 2018", "JUL 3, 2018", "JUL 2, 2018", "JUN 27, 2018", "JUN 21, 2018", "JUN 21, 2018", "JUN 20, 2018", "JUL 19, 2018", "JUN 6, 2018", "JUN 5, 2018", "JUN 1, 2018", "MAY 11, 2018", "MAY 11, 2018", "MAY 10, 2018", "MAY 10, 2018", "JUN 6, 2018", "APR 27, 2018", "APR 27, 2018", "APR 26, 2018", "APR 26, 2018", "APR 25, 2018", "APR 23, 2018", "APR 22, 2018", "MAY 4, 2018", "APR 17, 2018", "APR 16, 2018", "APR 16, 2018", "APR 16, 2018", "APR 16, 2018", "APR 16, 2018", "APR 18, 2018", "APR 16, 2018", "APR 11, 2018", "APR 7, 2018", "APR 6, 2018", "APR 5, 2018", "APR 4, 2018", "APR 4, 2018", "APR 16, 2018", "APR 3, 2018", "APR 3, 2018", "APR 2, 2018", "APR 2, 2018", "APR 2, 2018", "APR 2, 2018", "APR 2, 2018", "APR 4, 2018", "APR 2, 2018", "APR 2, 2018", "APR 2, 2018", "APR 2, 2018", "APR 2, 2018", "MAR 23, 2018", "MAR 14, 2018", "APR 2, 2018", "APR 2, 2018", "MAR 1, 2018", "FEB 23, 2018", "FEB 23, 2018", "FEB 23, 2018", "FEB 22, 2018", "MAR 1, 2018", "FEB 17, 2018", "FEB 16, 2018", "FEB 16, 2018", "FEB 16, 2018", "FEB 15, 2018", "FEB 14, 2018", "FEB 14, 2018", "FEB 20, 2018", "FEB 12, 2018", "FEB 12, 2018", "FEB 12, 2018", "FEB 9, 2018", "FEB 9, 2018", "FEB 6, 2018", "FEB 6, 2018", "FEB 13, 2018", "FEB 5, 2018", "FEB 5, 2018", "FEB 5, 2018", "FEB 5, 2018", "FEB 5, 2018", "FEB 5, 2018", "FEB 1, 2018", "FEB 5, 2018", "JAN 23, 2018", "JAN 19, 2018", "JAN 18, 2018", "JAN 17, 2018", "JAN 16, 2018", "JAN 15, 2018", "JAN 10, 2018", "JAN 29, 2018", "DEC 19, 2017", "DEC 7, 2017", "NOV 29, 2017", "NOV 29, 2017", "NOV 28, 2017", "NOV 28, 2017", "NOV 27, 2017", "JAN 10, 2018", "NOV 27, 2017", "NOV 14, 2017", "OCT 27, 2017", "OCT 27, 2017", "OCT 26, 2017", "OCT 26, 2017", "SEP 25, 2017", "NOV 27, 2017", "SEP 19, 2017", "SEP 5, 2017", "AUG 23, 2017", "AUG 22, 2017", "AUG 21, 2017", "AUG 15, 2017", "AUG 8, 2017", "SEP 21, 2017", "JUL 28, 2017", "JUL 28, 2017", "JUL 27, 2017", "JUL 19, 2017", "JUL 5, 2017", "JUL 3, 2017", "JUN 26, 2017", "JUL 29, 2017", "JUN 7, 2017", "JUN 7, 2017", "JUN 5, 2017", "MAY 31, 2017", "MAY 22, 2017", "MAY 4, 2017", "MAY 1, 2017", "JUN 12, 2017", "APR 24, 2017", "APR 7, 2017", "APR 3, 2017", "MAR 22, 2017", "MAR 17, 2017", "MAR 9, 2017", "MAR 6, 2017", "APR 28, 2017", "FEB 16, 2017", "FEB 14, 2017", "FEB 13, 2017", "FEB 6, 2017", "FEB 5, 2017", "JAN 18, 2017", "DEC 8, 2016", "FEB 16, 2017", "NOV 7, 2016", "NOV 7, 2016", "NOV 3, 2016", "NOV 1, 2016", "OCT 26, 2016", "OCT 21, 2016", "OCT 21, 2016", "NOV 22, 2016", "OCT 21, 2016", "OCT 20, 2016", "OCT 4, 2016", "SEP 29, 2016", "SEP 21, 2016", "SEP 15, 2016", "JUL 29, 2016", "OCT 21, 2016", "JUL 20, 2016", "JUL 12, 2016", "JUL 1, 2016", "JUN 13, 2016", "MAY 26, 2016", "MAY 20, 2016", "MAY 17, 2016", "JUL 25, 2016", "APR 7, 2016", "MAR 3, 2016", "FEB 26, 2016", "FEB 11, 2016", "FEB 9, 2016", "FEB 4, 2016", "FEB 4, 2016", "APR 29, 2016", "JAN 22, 2016", "JAN 21, 2016", "JAN 21, 2016", "JAN 21, 2016", "JAN 21, 2016", "JAN 21, 2016", "JAN 21, 2016", "JAN 27, 2016", "JAN 21, 2016", "JAN 21, 2016", "JAN 13, 2016", "JAN 9, 2016", "JAN 4, 2016", "DEC 17, 2015", "DEC 16, 2015", "JAN 21, 2016", "JAN 21, 2016", "JAN 21, 2016", "SEP 24, 2015", "SEP 18, 2015", "SEP 17, 2015", "AUG 26, 2015", "AUG 24, 2015", "OCT 28, 2015", "JUL 31, 2015", "JUL 27, 2015", "JUL 24, 2015", "JUL 19, 2015", "JUL 14, 2015", "JUN 23, 2015", "JUN 17, 2015", "AUG 20, 2015", "MAY 22, 2015", "MAY 20, 2015", "MAY 4, 2015", "APR 30, 2015", "APR 28, 2015", "APR 21, 2015", "APR 13, 2015", "MAY 26, 2015", "APR 9, 2015", "APR 8, 2015", "APR 7, 2015", "MAR 30, 2015", "MAR 25, 2015", "MAR 10, 2015", "APR 13, 2015", "APR 11, 2015", "APR 9, 2015", "FEB 23, 2015", "FEB 11, 2015", "FEB 10, 2015", "FEB 3, 2015", "MAR 3, 2015", "JAN 19, 2015", "JAN 11, 2015", "JAN 10, 2015", "JAN 8, 2015", "JAN 8, 2015", "JAN 7, 2015", "JAN 7, 2015", "FEB 1, 2015", "DEC 24, 2014", "DEC 16, 2014", "DEC 8, 2014", "DEC 5, 2014", "NOV 14, 2014", "OCT 31, 2014", "SEP 18, 2014", "DEC 30, 2014", "SEP 4, 2014", "AUG 26, 2014", "AUG 26, 2014", "AUG 26, 2014", "AUG 14, 2014", "AUG 4, 2014", "JUL 30, 2014", "SEP 8, 2014", "JUN 19, 2014", "JUN 18, 2014", "JUN 18, 2014", "JUN 11, 2014", "JUN 6, 2014", "MAY 1, 2014", "JUL 21, 2014", "APR 30, 2014", "APR 16, 2014", "APR 11, 2014", "APR 10, 2014", "APR 10, 2014", "APR 10, 2014", "APR 10, 2014", "APR 30, 2014", "APR 9, 2014", "APR 9, 2014", "APR 9, 2014", "APR 9, 2014", "APR 9, 2014", "APR 8, 2014", "APR 8, 2014", "APR 9, 2014", "APR 9, 2014", "APR 8, 2014", "APR 8, 2014", "APR 8, 2014", "APR 8, 2014", "APR 8, 2014", "APR 8, 2014", "APR 8, 2014", "APR 8, 2014", "APR 8, 2014", "APR 8, 2014", "APR 8, 2014", "APR 8, 2014", "APR 8, 2014", "APR 8, 2014", "APR 8, 2014", "APR 8, 2014", "APR 7, 2014", "APR 4, 2014", "APR 4, 2014", "APR 4, 2014", "APR 3, 2014", "APR 8, 2014", "APR 1, 2014", "APR 1, 2014", "APR 1, 2014", "MAR 31, 2014", "MAR 31, 2014", "MAR 31, 2014", "MAR 31, 2014", "APR 3, 2014", "MAR 28, 2014", "MAR 28, 2014", "MAR 28, 2014", "MAR 28, 2014", "MAR 28, 2014", "MAR 27, 2014", "MAR 27, 2014", "MAR 31, 2014", "MAR 27, 2014", "MAR 27, 2014", "MAR 27, 2014", "MAR 26, 2014", "MAR 26, 2014", "MAR 25, 2014", "MAR 25, 2014", "MAR 27, 2014", "MAR 27, 2014", "MAR 24, 2014", "MAR 21, 2014", "MAR 21, 2014", "MAR 21, 2014", "MAR 21, 2014", "MAR 24, 2014", "MAR 21, 2014", "MAR 21, 2014", "MAR 21, 2014", "MAR 20, 2014", "MAR 20, 2014", "MAR 20, 2014", "MAR 20, 2014", "MAR 21, 2014", "MAR 20, 2014", "MAR 19, 2014", "MAR 19, 2014", "MAR 19, 2014", "MAR 18, 2014", "MAR 18, 2014", "MAR 18, 2014", "MAR 20, 2014", "MAR 18, 2014", "MAR 18, 2014", "MAR 18, 2014", "MAR 18, 2014", "MAR 18, 2014", "MAR 18, 2014", "MAR 17, 2014", "MAR 18, 2014", "MAR 18, 2014", "MAR 14, 2014", "MAR 14, 2014", "MAR 14, 2014", "MAR 14, 2014", "MAR 14, 2014", "MAR 13, 2014", "MAR 14, 2014", "MAR 13, 2014", "MAR 13, 2014", "MAR 12, 2014", "MAR 12, 2014", "MAR 11, 2014", "MAR 11, 2014", "MAR 10, 2014", "MAR 13, 2014", "MAR 10, 2014", "MAR 10, 2014", "MAR 10, 2014", "MAR 7, 2014", "MAR 7, 2014", "MAR 7, 2014", "MAR 6, 2014", "MAR 10, 2014", "MAR 6, 2014", "MAR 5, 2014", "MAR 5, 2014", "MAR 5, 2014", "MAR 5, 2014", "MAR 4, 2014", "MAR 4, 2014", "MAR 6, 2014", "MAR 3, 2014", "MAR 3, 2014", "FEB 28, 2014", "FEB 28, 2014", "FEB 28, 2014", "FEB 25, 2014", "FEB 24, 2014", "MAR 4, 2014", "MAR 3, 2014", "JAN 7, 2014", "JAN 2, 2014", "DEC 16, 2013", "DEC 3, 2013", "DEC 3, 2013", "FEB 24, 2014", "OCT 18, 2013", "OCT 15, 2013", "OCT 14, 2013", "OCT 9, 2013", "OCT 2, 2013", "SEP 30, 2013", "SEP 30, 2013", "NOV 1, 2013", "JUL 3, 2013", "MAY 31, 2013", "MAY 29, 2013", "MAY 29, 2013", "MAY 23, 2013", "MAY 23, 2013", "MAY 22, 2013", "JUL 26, 2013", "JUL 3, 2013", "MAY 20, 2013", "MAY 16, 2013", "MAY 15, 2013", "MAY 15, 2013", "MAY 15, 2013", "MAY 14, 2013", "MAY 21, 2013", "APR 29, 2013", "APR 23, 2013", "APR 23, 2013", "APR 18, 2013", "APR 17, 2013", "APR 17, 2013", "APR 17, 2013", "MAY 10, 2013", "APR 16, 2013", "APR 11, 2013", "FEB 27, 2013", "FEB 26, 2013", "FEB 25, 2013", "FEB 22, 2013", "FEB 22, 2013", "APR 17, 2013", "FEB 21, 2013", "FEB 21, 2013", "FEB 20, 2013", "FEB 20, 2013", "FEB 13, 2013", "FEB 12, 2013", "FEB 11, 2013", "FEB 22, 2013", "FEB 11, 2013", "FEB 8, 2013", "FEB 6, 2013", "FEB 4, 2013", "FEB 1, 2013", "FEB 1, 2013", "JAN 30, 2013", "FEB 11, 2013", "FEB 11, 2013", "JAN 15, 2013", "JAN 9, 2013", "JAN 4, 2013", "DEC 27, 2012", "NOV 16, 2012", "NOV 5, 2012", "JAN 23, 2013", "OCT 12, 2012", "OCT 2, 2012", "OCT 1, 2012", "SEP 28, 2012", "SEP 18, 2012", "SEP 17, 2012", "AUG 14, 2012", "OCT 26, 2012", "AUG 10, 2012", "JUL 31, 2012", "JUL 25, 2012", "JUL 11, 2012", "JUL 10, 2012", "JUL 2, 2012", "JUN 13, 2012", "AUG 14, 2012", "APR 30, 2012", "MAR 16, 2012", "MAR 6, 2012", "FEB 16, 2012", "FEB 15, 2012", "FEB 14, 2012", "FEB 6, 2012", "MAY 18, 2012", "FEB 3, 2012", "FEB 1, 2012", "JAN 31, 2012", "JAN 30, 2012", "JAN 5, 2012", "DEC 21, 2011", "DEC 21, 2011", "FEB 6, 2012", "OCT 3, 2011", "JUN 21, 2011", "JUN 21, 2011", "MAY 9, 2011", "MAY 9, 2011", "APR 15, 2011", "OCT 20, 2010", "NOV 15, 2011", "JUL 15, 2010", "JUN 9, 2010", "MAY 17, 2010", "APR 19, 2010", "OCT 20, 2010"], "Published Date": [], "Link": ["https://www.nasdaq.com/articles/iwds-holdings-could-mean-20-gain-potential-2020-05-18", "https://www.nasdaq.com/articles/first-week-of-july-17th-options-trading-for-alkermes-alks-2020-05-15", "https://www.nasdaq.com/articles/alkermes-plc-alks-q1-2020-earnings-call-transcript-2020-04-29", "https://www.nasdaq.com/articles/alkermes-withdraws-2020-guidance-quick-facts-2020-04-29", "https://www.nasdaq.com/articles/alkermes-plc-q1-adjusted-earnings-beat-estimates-2020-04-29", "https://www.nasdaq.com/articles/alkermes-q1-20-earnings-conference-call-at-8%3A00-am-et-2020-04-29", "https://www.nasdaq.com/articles/thursdays-etf-movers%3A-rem-fbt-2020-04-09", "https://www.nasdaq.com/articles/alkermes-to-present-at-cowen-and-co-health-care-conference-webcast-at-3%3A30-pm-2020-03-02", "https://www.nasdaq.com/articles/iwds-holdings-could-mean-20-gain-potential-2020-05-18", "https://www.nasdaq.com/articles/5-stock-sampler-review-a-palooza-2020-02-26", "https://www.nasdaq.com/articles/analysts-predict-19-upside-for-fbt-2020-02-14", "https://www.nasdaq.com/articles/alkermes-plc-alks-q4-2019-earnings-call-transcript-2020-02-14", "https://www.nasdaq.com/articles/alkermes-issues-fy20-outlook-in-line-with-estimates-quick-facts-2020-02-13", "https://www.nasdaq.com/articles/alkermes-plc-q4-adjusted-earnings-beat-estimates-2020-02-13", "https://www.nasdaq.com/articles/alkermes-q4-19-earnings-conference-call-at-8%3A00-am-et-2020-02-13", "https://www.nasdaq.com/articles/heres-why-alkermes-jumped-almost-11-today-2020-02-05", "https://www.nasdaq.com/articles/bullish-two-hundred-day-moving-average-cross-alks-2020-02-26", "https://www.nasdaq.com/articles/interesting-alks-put-and-call-options-for-march-20th-2020-01-22", "https://www.nasdaq.com/articles/alkermes-to-present-at-j.p.-morgan-healthcare-conference-webcast-at-12%3A00-pm-et-2020-01-15", "https://www.nasdaq.com/articles/analysts-see-12-upside-for-ftxh-2020-01-14", "https://www.nasdaq.com/articles/interesting-alks-put-and-call-options-for-august-2020-2019-12-24", "https://www.nasdaq.com/articles/analysts-see-11-gains-ahead-for-ftxh-2019-12-10", "https://www.nasdaq.com/articles/why-is-alkermes-stock-down-30-so-far-this-year-2019-11-27", "https://www.nasdaq.com/articles/why-is-alkermes-stock-down-30-so-far-this-year-2019-11-27-0", "https://www.nasdaq.com/articles/alkermes-becomes-oversold-alks-2020-01-24", "https://www.nasdaq.com/articles/analysts-predict-14-gains-ahead-for-the-holdings-of-eqal-2019-11-06", "https://www.nasdaq.com/articles/alkermes-says-fda-approves-vumerity-for-multiple-sclerosis-2019-10-30", "https://www.nasdaq.com/articles/alkermes-plc-alks-q3-2019-earnings-call-transcript-2019-10-23", "https://www.nasdaq.com/articles/alkermes-raises-fy19-adj.-earnings-outlook-to-incur-q4-charge-quick-facts-2019-10-23", "https://www.nasdaq.com/articles/alkermes-plc-q3-adjusted-earnings-beat-estimates-2019-10-23", "https://www.nasdaq.com/articles/alkermes-q3-19-earnings-conference-call-at-8%3A00-am-et-2019-10-23", "https://www.nasdaq.com/articles/better-buy%3A-biogen-vs.-amgen-2019-09-27", "https://www.nasdaq.com/articles/alkermes-to-acquire-rodin-therapeutics-quick-facts-2019-11-18", "https://www.nasdaq.com/articles/analysts-predict-14-gains-ahead-for-the-holdings-of-eqal-2019-11-06", "https://www.nasdaq.com/articles/alkermes-says-fda-approves-vumerity-for-multiple-sclerosis-2019-10-30", "https://www.nasdaq.com/articles/alks-settles-patent-suit-once-monthly-contraceptive-in-the-works-nbix-on-watch-2019-07-30", "https://www.nasdaq.com/articles/alkermes-bounces-back-but-not-enough-2019-07-26", "https://www.nasdaq.com/articles/alkermes-plc-alks-q2-2019-earnings-call-transcript-2019-07-25", "https://www.nasdaq.com/articles/alkermes-plc-q2-adjusted-earnings-beat-estimates-2019-07-25", "https://www.nasdaq.com/articles/first-week-of-october-18th-options-trading-for-alkermes-alks-2019-08-20", "https://www.nasdaq.com/articles/alkermes-becomes-oversold-alks-2019-06-06", "https://www.nasdaq.com/articles/alkermes-now-oversold-alks-2019-05-01", "https://www.nasdaq.com/articles/first-week-alks-june-21st-options-trading-2019-04-29", "https://www.nasdaq.com/articles/analysts-expect-14-gains-ahead-holdings-rxl-2019-04-29", "https://www.nasdaq.com/articles/alkermes-looks-ahead-growth-2019-04-26", "https://www.nasdaq.com/articles/alkermes-plc-alks-q1-2019-earnings-call-transcript-2019-04-26", "https://www.nasdaq.com/articles/health-care-sector-update-for-04-25-2019%3A-wstbmyexelalks-2019-04-25", "https://www.nasdaq.com/articles/biogen-raises-guidance-as-it-looks-to-the-pipeline-for-growth-2019-07-24", "https://www.nasdaq.com/articles/heres-why-shares-alkermes-sank-today-2019-04-25", "https://www.nasdaq.com/articles/health-care-sector-update-for-04-25-2019%3A-alksbmyexel-2019-04-25", "https://www.nasdaq.com/articles/alkermes-plc-q1-adjusted-earnings-beat-estimates-2019-04-25", "https://www.nasdaq.com/articles/alkermes-reports-positive-data-from-schizophrenia-study-2019-04-10", "https://www.nasdaq.com/articles/alkermes-says-long-acting-drugs-could-help-schizophrenics-stay-medication-longer-2019-04", "https://www.nasdaq.com/articles/long-acting-injectable-drugs-could-help-schizophrenics-stay-medication-longer-2019-04-09", "https://www.nasdaq.com/articles/alkermes-announces-positive-topline-results-alpine-study-2019-04-09", "https://www.nasdaq.com/articles/biogen-looks-23-clinical-programs-growth-2019-04-25", "https://www.nasdaq.com/articles/recro-pharma-falls-as-fda-denies-approval-to-pain-candidate-2019-03-26", "https://www.nasdaq.com/articles/alkermes-focuses-on-pipeline-depends-on-partners-for-funds-2019-03-21", "https://www.nasdaq.com/articles/biogen-bad-news-buy-now-2019-03-21", "https://www.nasdaq.com/articles/why-is-alkermes-alks-up-4.7-since-last-earnings-report-2019-03-16", "https://www.nasdaq.com/articles/allergans-depression-candidate-fails-in-studies-stock-down-2019-03-07", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-once-cmta-soar-on-merger-news-other-pipeline-updates-2019-02-27", "https://www.nasdaq.com/articles/alkermes-alks-and-biogens-nda-for-biib098-accepted-by-fda-2019-02-26", "https://www.nasdaq.com/articles/analysts-predict-10-gains-ahead-vug-2019-03-28", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-icpt-strong-on-nash-drug-data-collaborations-more-2019-02-20", "https://www.nasdaq.com/articles/alkermes-breaks-1-billion-2019-02-19", "https://www.nasdaq.com/articles/we-did-math-eqwm-can-go-55-2019-02-19", "https://www.nasdaq.com/articles/consumer-sector-update-02192019-morcndticptclvsalks-2019-02-19", "https://www.nasdaq.com/articles/health-care-sector-update-02192019-cndticptclvsalks-2019-02-19", "https://www.nasdaq.com/articles/tuesdays-etf-unusual-volume-pbe-2019-02-19", "https://www.nasdaq.com/articles/alkermes-alks-q4-earnings-revenues-surpass-estimates-2019-02-15", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-intercept-gilead-vertex-alkermes-and-clovis-2019-02-21", "https://www.nasdaq.com/articles/alkermes-plc-alks-q4-2018-earnings-conference-call-transcript-2019-02-14", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-gilead-vertex-celgene-alkermes-and-aveo-2019-02-07", "https://www.nasdaq.com/articles/analysts-estimate-alkermes-alks-to-report-a-decline-in-earnings%3A-what-to-look-out-for-2019", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-celgene-tops-in-q4-gilead-disappoints-alks-aveo-sink-2019-02-06", "https://www.nasdaq.com/articles/notable-wednesday-option-activity-alks-dmrc-ingn-2019-02-06", "https://www.nasdaq.com/articles/alkermes-sinks-as-fda-refuses-to-approve-depression-drug-2019-02-04", "https://www.nasdaq.com/articles/fda-declines-approve-alkermes-opioid-based-depression-drug-2019-02-01", "https://www.nasdaq.com/articles/alkermes-alks-q4-earnings-and-revenues-beat-estimates-2019-02-14", "https://www.nasdaq.com/articles/what-makes-alkermes-alks-a-new-buy-stock-2019-01-29", "https://www.nasdaq.com/articles/surprising-analyst-12-month-target-iwp-2019-01-17", "https://www.nasdaq.com/articles/cbm-or-alks%3A-which-is-the-better-value-stock-right-now-2019-01-09", "https://www.nasdaq.com/articles/biogen-begins-improved-dosing-regimen-on-tysabri-in-phase-iii-2019-01-04", "https://www.nasdaq.com/articles/4-fastest-growing-biotech-stocks-2019-2018-12-31", "https://www.nasdaq.com/articles/biotech-stocks-facing-fda-decision-january-2019-2018-12-24", "https://www.nasdaq.com/articles/relative-strength-alert-alkermes-2018-12-19", "https://www.nasdaq.com/articles/biogen-looks-2020-2019-01-30", "https://www.nasdaq.com/articles/implied-fbt-analyst-target-price-182-2018-12-17", "https://www.nasdaq.com/articles/alkermes-submits-nda-diroximel-fumarate-quick-facts-2018-12-17", "https://www.nasdaq.com/articles/health-care-sector-update-11292018-alkseyptjazz-2018-11-29", "https://www.nasdaq.com/articles/health-care-sector-update-11292018-tnxp-oncy-eypt-alks-2018-11-29", "https://www.nasdaq.com/articles/noteworthy-thursday-option-activity-alks-cdxs-splk-2018-11-29", "https://www.nasdaq.com/articles/health-care-sector-update-11292018-oncyeyptalks-2018-11-29", "https://www.nasdaq.com/articles/alkermes-alks-down-14.2-since-last-earnings-report%3A-can-it-rebound-2018-11-22", "https://www.nasdaq.com/articles/alkermes-biogen-submit-nda-to-fda-for-multiple-sclerosis-drug-2018-12-18", "https://www.nasdaq.com/articles/just-how-bad-alkermes-depression-drug-setback-2018-11-12", "https://www.nasdaq.com/articles/noteworthy-friday-option-activity-amba-abus-alks-2018-11-09", "https://www.nasdaq.com/articles/jazz-pharma-jazz-beats-on-q3-earnings-lowers-sales-view-2018-11-08", "https://www.nasdaq.com/articles/why-alkermes-depression-drug-stumbled-and-how-illumina-plans-profit-ma-2018-11-08", "https://www.nasdaq.com/articles/noteworthy-thursday-option-activity-tree-lgih-alks-2018-11-01", "https://www.nasdaq.com/articles/notable-wednesday-option-activity-alks-fang-eri-2018-10-24", "https://www.nasdaq.com/articles/sum-parts-size-could-be-worth-95-2018-11-16", "https://www.nasdaq.com/articles/alkermes-alks-exceeds-q3-earnings-estimates-raises-outlook-2018-10-23", "https://www.nasdaq.com/articles/alkermes-alks-beats-q3-earnings-and-revenue-estimates-2018-10-23", "https://www.nasdaq.com/articles/alkermes-plc-alks-q3-2018-earnings-conference-call-transcript-2018-10-23", "https://www.nasdaq.com/articles/alkermes-boasts-strong-portfolio-and-impressive-pipeline-2018-10-19", "https://www.nasdaq.com/articles/ebs-or-alks%3A-which-is-the-better-value-stock-right-now-2018-10-18", "https://www.nasdaq.com/articles/fda-sets-action-date-for-recros-pain-management-candidate-2018-10-09", "https://www.nasdaq.com/articles/vistagen-up-on-fast-track-designation-to-pain-candidate-2018-10-04", "https://www.nasdaq.com/articles/alkermes-makes-financial-progress-its-pipeline-moves-forward-2018-10-24", "https://www.nasdaq.com/articles/are-options-traders-betting-on-a-big-move-in-alkermes-alks-stock-2018-09-19", "https://www.nasdaq.com/articles/alkermes-expands-study-to-evaluate-alks-4230-keytruda-combo-2018-09-11", "https://www.nasdaq.com/articles/relative-strength-alert-alkermes-2018-09-07", "https://www.nasdaq.com/articles/notable-tuesday-option-activity-alks-nclh-ehth-2018-08-14", "https://www.nasdaq.com/articles/collaborations-help-alkermes-flip-profitability-2018-07-27", "https://www.nasdaq.com/articles/whats-in-store-for-universal-healths-uhs-q2-earnings-2018-07-20", "https://www.nasdaq.com/articles/whats-in-the-cards-for-hca-healthcare-hca-in-q2-earnings-2018-07-20", "https://www.nasdaq.com/articles/allergan-eyes-vraylar-label-expansion-fda-accepts-snda-2018-09-27", "https://www.nasdaq.com/articles/company-news-for-jul-3-2018-2018-07-03", "https://www.nasdaq.com/articles/alkermes-aristada-initio-approved-by-fda-for-schizophrenia-2018-07-03", "https://www.nasdaq.com/articles/morning-movers-las-vegas-sands-tumbles-tesla-jumps-alkermes-soars-2018-07-02", "https://www.nasdaq.com/articles/oversold-conditions-alkermes-alks-2018-06-27", "https://www.nasdaq.com/articles/why-alkermes-tumbled-15-today-2018-06-21", "https://www.nasdaq.com/articles/why-stampscom-iqiyi-and-alkermes-slumped-today-2018-06-21", "https://www.nasdaq.com/articles/first-week-alks-february-2019-options-trading-2018-06-20", "https://www.nasdaq.com/articles/is-a-beat-in-the-cards-for-centene-cnc-in-q2-earnings-2018-07-19", "https://www.nasdaq.com/articles/health-care-sector-update-06062018-itciclrbalksbiib-2018-06-06", "https://www.nasdaq.com/articles/analysts-forecast-12-upside-eqwm-2018-06-05", "https://www.nasdaq.com/articles/key-fda-events-in-june-investors-need-to-watch-out-for-2018-06-01", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-seagate-grafton-ingersoll-rand-and-alkermes-2018-05-11", "https://www.nasdaq.com/articles/notable-friday-option-activity-sgms-csx-alks-2018-05-11", "https://www.nasdaq.com/articles/4-top-stocks-buy-irish-economy-gathers-steam-2018-05-10", "https://www.nasdaq.com/articles/4-top-stocks-buy-irish-economy-gathers-steam-2018-05-10-0", "https://www.nasdaq.com/articles/health-care-sector-update-06062018-entaitciclrbalksbiib-2018-06-06", "https://www.nasdaq.com/articles/alkermes-alks-reports-wider-than-expected-loss-in-q1-2018-04-27", "https://www.nasdaq.com/articles/alkermes-alks-q1-2018-earnings-conference-call-transcript-2018-04-27", "https://www.nasdaq.com/articles/biomarin-bmrn-q1-earnings-lower-than-expected-sales-beat-2018-04-26", "https://www.nasdaq.com/articles/after-bumpy-ride-alkermes-confirms-its-back-track-2018-04-26", "https://www.nasdaq.com/articles/interesting-alks-put-and-call-options-june-15th-2018-04-25", "https://www.nasdaq.com/articles/alkermes-promising-depression-drug-back-track-2018-04-23", "https://www.nasdaq.com/articles/johnson-johnsons-first-quarter-2018-earnings-review-2018-04-22", "https://www.nasdaq.com/articles/analysts-anticipate-vv-hit-136-2018-05-04", "https://www.nasdaq.com/articles/alkermes-rallies-as-fda-accepts-nda-for-depression-drug-2018-04-17", "https://www.nasdaq.com/articles/mid-day-market-update-crude-oil-down-over-1-eldorado-resorts-shares-surge-2018-04-16", "https://www.nasdaq.com/articles/it-time-give-alkermes-2018-04-16", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-open-higher-bank-america-earnings-top-estimates-2018-04", "https://www.nasdaq.com/articles/morning-movers-bank-america-gains-earnings-costco-rises-upgrade-2018-04-16", "https://www.nasdaq.com/articles/health-care-sector-update-04162018-alks-cldx-apri-2018-04-16", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-alks-up-cldx-down-alxn-to-acquire-wilson-therapeutics-2018-04-18", "https://www.nasdaq.com/articles/health-care-sector-update-04162018-cldxalksapri-2018-04-16", "https://www.nasdaq.com/articles/alkermes-has-some-decisions-make-2018-04-11", "https://www.nasdaq.com/articles/will-shire-be-bought-out-2018-04-07", "https://www.nasdaq.com/articles/5-healthcare-stocks-buy-today-2018-04-06", "https://www.nasdaq.com/articles/fda-refuses-alkermes-depression-drug-review%3A-4-stocks-in-focus-2018-04-05", "https://www.nasdaq.com/articles/allergans-vraylar-meets-endpoints-in-bipolar-i-phase-iii-2018-04-04", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-edge-falls-alks-down-fda-oks-amgn-drug-label-expansion-2018-04-04", "https://www.nasdaq.com/articles/health-care-sector-update-04162018-shpscldxalksapri-2018-04-16", "https://www.nasdaq.com/articles/company-news-for-april-3-2018-2018-04-03", "https://www.nasdaq.com/articles/alkermes-sinks-as-fda-refuses-depression-drug-review-2018-04-03", "https://www.nasdaq.com/articles/alkermes-enters-oversold-territory-alks-2018-04-02", "https://www.nasdaq.com/articles/mondays-etf-unusual-volume-eqal-2018-04-02", "https://www.nasdaq.com/articles/mondays-etf-movers-gdxj-fbt-2018-04-02", "https://www.nasdaq.com/articles/alks-crosses-below-key-moving-average-level-2018-04-02", "https://www.nasdaq.com/articles/heres-why-alkermes-plc-and-intra-cellular-therapies-inc-are-crashing-today-2018-04-02", "https://www.nasdaq.com/articles/alkermes-bad-news-could-be-good-news-johnson-johnson-2018-04-04", "https://www.nasdaq.com/articles/morning-movers-looks-more-trouble-ahead-2018-04-02", "https://www.nasdaq.com/articles/pre-market-most-active-apr-2-2018-tvix-qqq-alks-tsla-wmt-mu-sqqq-baba-cht-bac-fit-wbt-2018", "https://www.nasdaq.com/articles/what-happened-stock-market-today-2018-04-02", "https://www.nasdaq.com/articles/noteworthy-monday-option-activity-tsla-lfin-alks-2018-04-02", "https://www.nasdaq.com/articles/mid-afternoon-market-update-dow-falls-over-500-points-crude-oil-down-25-2018-04-02", "https://www.nasdaq.com/articles/spdr-sp-biotech-etf-experiences-big-inflow-2018-03-23", "https://www.nasdaq.com/articles/commit-purchase-alkermes-45-earn-115-annualized-using-options-2018-03-14", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-open-lower-cal-maine-foods-posts-upbeat-sales-2018-04-02", "https://www.nasdaq.com/articles/morning-movers-looks-more-trouble-ahead-2018-04-02", "https://www.nasdaq.com/articles/health-care-sector-update-03012018-nvaxalksatra-2018-03-01", "https://www.nasdaq.com/articles/better-buy-biogen-inc-vs-celgene-corporation-2018-02-23", "https://www.nasdaq.com/articles/3-top-healthcare-stocks-buy-right-now-2018-02-23", "https://www.nasdaq.com/articles/first-week-april-20th-options-trading-alkermes-alks-2018-02-23", "https://www.nasdaq.com/articles/why-alkermes-sinking-today-2018-02-22", "https://www.nasdaq.com/articles/5-stocks-world-really-needs-right-now-1-year-performance-review-2018-03-01", "https://www.nasdaq.com/articles/3-biotech-stocks-soared-week-are-they-buys-2018-02-17", "https://www.nasdaq.com/articles/notable-friday-option-activity-true-bjri-alks-2018-02-16", "https://www.nasdaq.com/articles/stocks-watch-alkermes-sees-relative-strength-rating-rise-85-2018-02-16", "https://www.nasdaq.com/articles/alkermes-gets-ibd-stock-rating-upgrade-2018-02-16", "https://www.nasdaq.com/articles/alkermes-alks-beats-q4-earnings-revenue-estimates-2018-02-15", "https://www.nasdaq.com/articles/do-options-traders-know-something-about-alkermes-alks-stock-we-dont-2018-02-14", "https://www.nasdaq.com/articles/heres-why-alkermes-spiked-today-2018-02-14", "https://www.nasdaq.com/articles/alkermes-sets-itself-transformative-2018-2018-02-20", "https://www.nasdaq.com/articles/shire-shpg-to-report-q4-earnings%3A-whats-in-the-cards-2018-02-12", "https://www.nasdaq.com/articles/why-earnings-season-could-be-great-for-alkermes-alks-2018-02-12", "https://www.nasdaq.com/articles/will-ocaliva-sales-dampen-intercepts-icpt-q4-earnings-2018-02-12", "https://www.nasdaq.com/articles/agios-pharmaceuticals-agio-q4-earnings%3A-whats-in-store-2018-02-09", "https://www.nasdaq.com/articles/zoetis-zts-warming-up-to-q4-earnings%3A-whats-in-store-2018-02-09", "https://www.nasdaq.com/articles/alkermes-breaks-below-200-day-moving-average-notable-alks-2018-02-06", "https://www.nasdaq.com/articles/5-biotech-stocks-set-to-trump-estimates-this-earnings-season-2018-02-06", "https://www.nasdaq.com/articles/pre-market-earnings-report-february-14-2018-shpg-hlt-dps-iqv-teck-tap-cms-wyn-bg-aer-ipg", "https://www.nasdaq.com/articles/keryx-kerx-warming-up-to-q4-earnings%3A-whats-in-store-2018-02-05", "https://www.nasdaq.com/articles/alkermes-reaches-analyst-target-price-2018-02-05", "https://www.nasdaq.com/articles/is-a-beat-in-store-for-alexion-alxn-this-earnings-season-2018-02-05", "https://www.nasdaq.com/articles/strength-seen-in-alkermes-alks%3A-stock-soars-8.7-2018-02-05", "https://www.nasdaq.com/articles/explains-why-alkermes-plc-falling-today-2018-02-05", "https://www.nasdaq.com/articles/why-wells-fargo-advanced-micro-devices-and-alkermes-slumped-today-2018-02-05", "https://www.nasdaq.com/articles/alkermes-submits-nda-for-depression-candidate-to-the-fda-2018-02-01", "https://www.nasdaq.com/articles/is-a-beat-in-the-cards-for-immunogen-imgn-in-q4-earnings-2018-02-05", "https://www.nasdaq.com/articles/3-pharma-and-biotech-stocks-to-watch-out-for-in-2018-2018-01-23", "https://www.nasdaq.com/articles/spectrum-pharmaceuticals-up-134-in-6-months%3A-heres-why-2018-01-19", "https://www.nasdaq.com/articles/3-biotech-stocks-start-healthy-18-will-rally-last-2018-01-18", "https://www.nasdaq.com/articles/blackrock-pier-one-imports-alkermes-vertex-pharmaceuticals-and-agenus-highlighted-as-zacks", "https://www.nasdaq.com/articles/3-biotech-stocks-start-healthy-in-18%3A-will-the-rally-last-2018-01-16", "https://www.nasdaq.com/articles/3-pharma-and-biotech-stocks-watch-out-2018-2018-01-15", "https://www.nasdaq.com/articles/health-care-sector-update-01102018-jnjalksadvlaphn-2018-01-10", "https://www.nasdaq.com/articles/3-biotech-stocks-buy-2018-2018-01-29", "https://www.nasdaq.com/articles/allergans-vraylar-positive-for-bipolar-disease-in-phase-iii-2017-12-19", "https://www.nasdaq.com/articles/surging-earnings-estimates-signal-good-news-for-alkermes-alks-2017-12-07", "https://www.nasdaq.com/articles/biotech-stock-roundup-regeneron-down-eylea-data-biogen-alkermes-ms-deal-2017-11-29", "https://www.nasdaq.com/articles/biogen-acquires-worldwide-license-for-alkermes-ms-candidate-revised-2017-11-29", "https://www.nasdaq.com/articles/biogen-acquires-worldwide-license-for-alkermes-ms-candidate-2017-11-28", "https://www.nasdaq.com/articles/why-is-alkermes-alks-down-8.3-since-the-last-earnings-report-2017-11-28", "https://www.nasdaq.com/articles/biogens-multiple-sclerosis-franchise-getting-new-lease-life-2017-11-27", "https://www.nasdaq.com/articles/health-care-sector-update-01102018-aphbadvlalks-2018-01-10", "https://www.nasdaq.com/articles/biogen-inc-buys-its-way-out-competition-2017-11-27", "https://www.nasdaq.com/articles/allergans-vraylar-gets-fda-nod-for-maintenance-therapy-2017-11-14", "https://www.nasdaq.com/articles/alkermes-alks-beats-q3-earnings-estimates-cuts-sales-view-2017-10-27", "https://www.nasdaq.com/articles/alkermes-alks-in-focus%3A-stock-moves-11.1-higher-2017-10-27", "https://www.nasdaq.com/articles/clear-reason-alkermes-plcs-shares-jumped-much-12-2017-10-26", "https://www.nasdaq.com/articles/alkermes-reports-mixed-results-updates-guidance-2017-10-26", "https://www.nasdaq.com/articles/allergans-agn-vraylar-gets-rtf-from-fda-new-data-for-cvc-2017-09-25", "https://www.nasdaq.com/articles/interesting-alks-put-and-call-options-january-2018-2017-11-27", "https://www.nasdaq.com/articles/alkermes-aristada-shows-better-results-to-treat-schizophrenia-2017-09-19", "https://www.nasdaq.com/articles/alkermes-now-oversold-alks-2017-09-05", "https://www.nasdaq.com/articles/biotech-stock-roundup-eu-label-expansion-alexion-biib-facing-drug-price-probe-2017-08-23", "https://www.nasdaq.com/articles/alkermes-initiates-rolling-submission-of-depression-drug-2017-08-22", "https://www.nasdaq.com/articles/surprising-analyst-12-month-target-iwp-2017-08-21", "https://www.nasdaq.com/articles/what-you-see-and-what-you-get-neurology-perception-2017-08-15", "https://www.nasdaq.com/articles/alkermes-enters-oversold-territory-alks-2017-08-08", "https://www.nasdaq.com/articles/implied-bbh-analyst-target-price-150-2017-09-21", "https://www.nasdaq.com/articles/alkermes-alks-q2-loss-narrower-than-expected-sales-beat-2017-07-28", "https://www.nasdaq.com/articles/alkermes-continues-execute-2017-07-28", "https://www.nasdaq.com/articles/alks-crosses-below-key-moving-average-level-2017-07-27", "https://www.nasdaq.com/articles/we-did-math-fbt-can-go-127-2017-07-19", "https://www.nasdaq.com/articles/biotech-stock-roundup-cara-plunges-study-data-regulatory-updates-more-2017-07-05", "https://www.nasdaq.com/articles/alkermes-presents-phase-iii-data-on-schizophrenia-candidate-2017-07-03", "https://www.nasdaq.com/articles/minerva-on-track-to-initiate-phase-iii-schizophrenia-study-2017-06-26", "https://www.nasdaq.com/articles/3-biotech-stocks-enterprising-investors-2017-07-29", "https://www.nasdaq.com/articles/alkermes-gets-fda-nod-for-two-month-dose-of-aristada-2017-06-07", "https://www.nasdaq.com/articles/can-alkermes-latest-approval-spark-rally-2017-06-07", "https://www.nasdaq.com/articles/key-fda-events-watch-out-jun-2017-2017-06-05", "https://www.nasdaq.com/articles/alkermes-alks-up-2.5-since-earnings-report%3A-can-it-continue-2017-05-31", "https://www.nasdaq.com/articles/woodford-investment-management-llp-buys-gilead-sciences-inc-bioverativ-inc-biogen-inc", "https://www.nasdaq.com/articles/analysts-forecast-12-upside-bbh-2017-05-04", "https://www.nasdaq.com/articles/alkermes-revenue-jumps-22-2017-05-01", "https://www.nasdaq.com/articles/alkermes-commences-phase-iii-study-for-schizophrenia-drug-2017-06-12", "https://www.nasdaq.com/articles/meditor-group-ltd-buys-celldex-therapeutics-sells-vivus-2017-04-24", "https://www.nasdaq.com/articles/5-drug-stocks-your-portfolio-world-health-day-2017-04-07", "https://www.nasdaq.com/articles/3-top-biotech-stocks-buy-april-2017-04-03", "https://www.nasdaq.com/articles/commit-purchase-alkermes-50-earn-119-annualized-using-options-2017-03-22", "https://www.nasdaq.com/articles/alkermes-starts-phase-iii-study-to-treat-multiple-sclerosis-2017-03-17", "https://www.nasdaq.com/articles/allergans-agn-vraylar-snda-accepted-for-review-by-fda-2017-03-09", "https://www.nasdaq.com/articles/4-things-alkermes-wants-investors-know-2017-03-06", "https://www.nasdaq.com/articles/alkermes-alks-q1-loss-wider-than-expected-sales-miss-2017-04-28", "https://www.nasdaq.com/articles/alkermes-alks-q4-loss-narrower-than-expectations-sales-beat-2017-02-16", "https://www.nasdaq.com/articles/pre-market-earnings-report-february-15-2017-pep-adi-hlt-teck-etr-trgp-bg-wyn-alks-hun-fun", "https://www.nasdaq.com/articles/why-sage-therapeutics-jumped-today-2017-02-13", "https://www.nasdaq.com/articles/alkermes-poised-comeback-2017-2017-02-06", "https://www.nasdaq.com/articles/naltrexone-showing-more-potential-drug-addiction-treatment-market-2017-02-05", "https://www.nasdaq.com/articles/implied-vug-analyst-target-price-126-2017-01-18", "https://www.nasdaq.com/articles/5-drug-stocks-to-avoid-as-trump-vows-to-lower-drug-prices-2016-12-08", "https://www.nasdaq.com/articles/alkermes-revenue-soars-projects-exciting-year-ahead-2017-02-16", "https://www.nasdaq.com/articles/commit-purchase-alkermes-43-earn-145-annualized-using-options-2016-11-07", "https://www.nasdaq.com/articles/alkermes-plc-sales-rise-losses-fall-and-pipeline-moves-forward-2016-11-07", "https://www.nasdaq.com/articles/alkermes-alks-q3-loss-in-line-sales-miss-16-view-intact-2016-11-03", "https://www.nasdaq.com/articles/drug-stocks-to-watch-for-earnings-on-nov-2-agn-zts-more-2016-11-01", "https://www.nasdaq.com/articles/biotech-stock-roundup-clinical-holds-hit-inovio-aduro-vertex-q3-results-miss-estimates", "https://www.nasdaq.com/articles/3-stocks-to-watch-on-friday%3A-alkermes-plc-alks-microsoft-corporation-msft-and-time-warner", "https://www.nasdaq.com/articles/alkermes-depression-candidate-positive-in-phase-iii-study-2016-10-21", "https://www.nasdaq.com/articles/acorda-stops-post-stroke-development-program-on-ampyra-2016-11-22", "https://www.nasdaq.com/articles/health-care-sector-update-10212016-qtntalksmwbo-2016-10-21", "https://www.nasdaq.com/articles/after-hours-most-active-oct-20-2016-bac-bbva-msft-ca-ctsh-qqq-alks-pypl-vz-pbr-kkr-pfe", "https://www.nasdaq.com/articles/alkermes-commences-metabolic-study-on-schizophrenia-drug-2016-10-04", "https://www.nasdaq.com/articles/intra-cellular-reports-poor-phase-iii-schizophrenia-data-2016-09-29", "https://www.nasdaq.com/articles/biotech-stock-roundup-tobira-soars-acquisition-deal-fda-says-yes-sarepta-dmd-drug-2016-09", "https://www.nasdaq.com/articles/moving-average-crossover-alert%3A-alkermes-alks-2016-09-15", "https://www.nasdaq.com/articles/alkermes-alks-posts-narrower-q2-loss-ups-2016-outlook-2016-07-29", "https://www.nasdaq.com/articles/health-care-sector-update-10212016-mdrxalksmwbo-2016-10-21", "https://www.nasdaq.com/articles/xbi-jpxn-big-etf-outflows-2016-07-20", "https://www.nasdaq.com/articles/spdr-sp-biotech-etf-experiences-big-inflow-2016-07-12", "https://www.nasdaq.com/articles/noteworthy-etf-outflows-xbi-ions-alks-icpt-2016-07-01", "https://www.nasdaq.com/articles/look-under-hood-jkh-has-11-upside-2016-06-13", "https://www.nasdaq.com/articles/alkermes-begins-phase-i-study-on-immuno-oncology-drug-2016-05-26", "https://www.nasdaq.com/articles/fridays-etf-movers-xbi-rhs-2016-05-20", "https://www.nasdaq.com/articles/xbi-mdvn-nbix-alks-etf-inflow-alert-2016-05-17", "https://www.nasdaq.com/articles/alkermes-alks-shares-cross-above-200-dma-2016-07-25", "https://www.nasdaq.com/articles/analysts-anticipate-mtum-will-reach-81-2016-04-07", "https://www.nasdaq.com/articles/why-alkermes-alks-stock-might-be-a-great-pick-2016-03-03", "https://www.nasdaq.com/articles/alkermes-q4-loss-narrower-than-expected-updates-pipeline-2016-02-26", "https://www.nasdaq.com/articles/alkermes-alks-3831-in-2nd-phase-iii-study-for-schizophrenia-2016-02-11", "https://www.nasdaq.com/articles/commit-purchase-alkermes-23-earn-136-annualized-using-options-2016-02-09", "https://www.nasdaq.com/articles/why-did-biotech-fall-cliff-january-2016-02-04", "https://www.nasdaq.com/articles/sum-pieces-pdp-could-be-worth-45-2016-02-04", "https://www.nasdaq.com/articles/alkermes-alks-reports-narrower-than-expected-q1-loss-2016-04-29", "https://www.nasdaq.com/articles/alkermes-hit-52-week-low-on-unfavorable-phase-iii-data-2016-01-22", "https://www.nasdaq.com/articles/thursdays-etf-movers-xop-bbh-2016-01-21", "https://www.nasdaq.com/articles/mid-day-market-update-us-stocks-turn-higher-plexus-shares-gain-strong-results-2016-01-21", "https://www.nasdaq.com/articles/heres-why-alkermes-stock-tanking-today-2016-01-21", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-drop-verizon-profit-tops-estimates-2016-01-21", "https://www.nasdaq.com/articles/us-stock-futures-move-black-closer-open-jobless-claims-rise-more-expected-2016-01-21", "https://www.nasdaq.com/articles/pre-market-most-active-jan-21-2016-tvix-xiv-qqq-alks-cbx-smfg-ubs-zfgn-sny-bac-nok-siri", "https://www.nasdaq.com/articles/alkermes-initiates-early-stage-study-on-alzheimers-drug-2016-01-27", "https://www.nasdaq.com/articles/why-alkermes-scholastic-and-mgic-investment-slumped-today-2016-01-21", "https://www.nasdaq.com/articles/mid-afternoon-market-update-crude-oil-surges-over-4-alkermes-shares-slide-following", "https://www.nasdaq.com/articles/arena-boehringer-ingelheim-ink-deal-schizophrenia-in-focus-2016-01-13", "https://www.nasdaq.com/articles/5-biotech-predictions-2016-2016-01-09", "https://www.nasdaq.com/articles/alkermes-upgraded-to-hold-on-encouraging-portfolio-update-2016-01-04", "https://www.nasdaq.com/articles/alkermes-hits-52-week-high-on-pipeline-update-aristada-2015-12-17", "https://www.nasdaq.com/articles/health-care-sector-update-12162015-mrns-biib-alks-2015-12-16", "https://www.nasdaq.com/articles/us-equities-futures-point-slightly-lower-europe-cling-gains-2016-01-21", "https://www.nasdaq.com/articles/why-alkermes-scholastic-and-mgic-investment-slumped-today-2016-01-21", "https://www.nasdaq.com/articles/first-week-may-2016-options-trading-alkermes-alks-2015-09-24", "https://www.nasdaq.com/articles/notable-two-hundred-day-moving-average-cross-alks-2015-09-24", "https://www.nasdaq.com/articles/allergan-gedeons-vraylar-gets-fda-nod-for-mental-disorders-2015-09-18", "https://www.nasdaq.com/articles/intra-cellular-up-on-positive-data-from-schizophrenia-study-2015-09-17", "https://www.nasdaq.com/articles/biotech-stock-roundup-acorda-gains-patent-issues-vital-crushed-liver-data-2015-08-26", "https://www.nasdaq.com/articles/alkermes-alks-aristada-review-date-postponed-by-fda-2015-08-24", "https://www.nasdaq.com/articles/alks-makes-bullish-cross-above-critical-moving-average-2015-10-28", "https://www.nasdaq.com/articles/alkermes-reports-wider-q2-loss-increases-guidance-analyst-blog-2015-07-31", "https://www.nasdaq.com/articles/will-mckesson-mck-keep-the-earnings-streak-alive-analyst-blog-2015-07-27", "https://www.nasdaq.com/articles/will-express-scripts-esrx-miss-earnings-estimates-in-q2-analyst-blog-2015-07-24", "https://www.nasdaq.com/articles/why-i-think-alkermes-could-be-top-performing-stock-ahead-2016-2015-07-19", "https://www.nasdaq.com/articles/midyear-report-card-grading-my-biotech-predictions-2015-2015-07-14", "https://www.nasdaq.com/articles/first-week-alks-february-2016-options-trading-2015-06-23", "https://www.nasdaq.com/articles/alkermes-alks-in-focus%3A-stock-rises-10.1-in-session-tale-of-the-tape-2015-06-17", "https://www.nasdaq.com/articles/alks-crosses-below-key-moving-average-level-2015-08-20", "https://www.nasdaq.com/articles/3-stocks-poised-to-grow-in-the-schizophrenia-market-analyst-blog-2015-05-22", "https://www.nasdaq.com/articles/first-week-alks-july-17th-options-trading-2015-05-20", "https://www.nasdaq.com/articles/alkermes-q1-loss-narrower-than-expected-maintains-view-analyst-blog-2015-05-04", "https://www.nasdaq.com/articles/alks-makes-notable-cross-below-critical-moving-average-2015-04-30", "https://www.nasdaq.com/articles/5-biotech-stocks-to-avoid-after-mondays-slump-analyst-blog-2015-04-28", "https://www.nasdaq.com/articles/first-week-alks-june-19th-options-trading-2015-04-21", "https://www.nasdaq.com/articles/midday-update-stocks-holding-slim-gains-ahead-upcoming-earnings-glut-2015-04-13", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-johnson-johnson-astrazeneca-acadia-pharmaceuticals", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-alkermes-regulus-juno-therapeutics-targacept-and-gilead", "https://www.nasdaq.com/articles/biotech-stock-roundup-alkermes-drug-fares-well-targacept-slides-deal-termination-analyst", "https://www.nasdaq.com/articles/alkermes-reports-encouraging-data-on-schizophrenia-drug-analyst-blog-2015-04-07", "https://www.nasdaq.com/articles/biogen-abbvies-ms-drug-zinbryta-under-review-in-the-eu-analyst-blog-2015-03-30", "https://www.nasdaq.com/articles/interesting-alks-put-and-call-options-november-20th-2015-03-25", "https://www.nasdaq.com/articles/alkermes-streamlines-operations-revises-2015-guidance-analyst-blog-2015-03-10", "https://www.nasdaq.com/articles/health-care-sector-update-04132015-neot-aezs-reph-2015-04-13", "https://www.nasdaq.com/articles/new-drug-could-halt-weight-gain-patients-taking-these-antipsychotics-2015-04-11", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-alkermes-regulus-juno-therapeutics-targacept-and-gilead", "https://www.nasdaq.com/articles/pre-market-earnings-report-february-24-2015-hd-cmcsa-vrx-bmo-amt-ecl-cmcsk-m-pll-alks-wlk", "https://www.nasdaq.com/articles/biotech-stock-roundup-achillion-impresses-hcv-data-regeneron-4q-results-top-estimates", "https://www.nasdaq.com/articles/alkermes-reports-positive-data-on-multiple-sclerosis-drug-analyst-blog-2015-02-10", "https://www.nasdaq.com/articles/tuesdays-etf-movers-vlue-fbt-2015-02-03", "https://www.nasdaq.com/articles/alkermes-intends-to-add-new-candidate-to-its-pipeline-analyst-blog-2015-03-03", "https://www.nasdaq.com/articles/alkermes-plc-alks-in-focus%3A-stock-moves-6.6-higher-tale-of-the-tape-2015-01-19", "https://www.nasdaq.com/articles/5-predictions-biotechnology-stocks-2015-2015-01-11", "https://www.nasdaq.com/articles/cancel-jpmorgan-plenty-pre-conference-data-and-deals-digest-2015-01-10", "https://www.nasdaq.com/articles/great-news-exciting-new-drug-depression-may-be-way-2015-01-08", "https://www.nasdaq.com/articles/alkermes-soars-on-positive-schizophrenia-drug-results-analyst-blog-2015-01-08", "https://www.nasdaq.com/articles/biotech-stock-roundup-kite-flies-high-amgen-deal-isis-soars-jj-collaboration-analyst-blog", "https://www.nasdaq.com/articles/alkermes-gains-on-positive-depression-drug-study-data-analyst-blog-2015-01-07", "https://www.nasdaq.com/articles/could-be-game-changing-news-battle-against-multiple-sclerosis-2015-02-01", "https://www.nasdaq.com/articles/first-week-alks-august-2015-options-trading-2014-12-24", "https://www.nasdaq.com/articles/alkermes-starts-phase-i-study-on-schizophrenia-candidate-analyst-blog-2014-12-16", "https://www.nasdaq.com/articles/3-biotech-etfs-rally-merger-news-2014-12-08", "https://www.nasdaq.com/articles/first-week-january-2015-options-trading-alkermes-alks-2014-12-05", "https://www.nasdaq.com/articles/biotech-and-yet-weve-just-begun-2014-11-14", "https://www.nasdaq.com/articles/alkermes-incurs-wider-q3-loss-but-revenues-grow-y-y-analyst-blog-2014-10-31", "https://www.nasdaq.com/articles/alks-crosses-above-key-moving-average-level-2014-09-18", "https://www.nasdaq.com/articles/noteworthy-etf-outflows-vb-mdvn-coo-alks-2014-12-30", "https://www.nasdaq.com/articles/alkermes-completes-enrolment-for-phase-ii-alks-3831-study-analyst-blog-2014-09-04", "https://www.nasdaq.com/articles/sector-update-health-care-shares-flat-pre-market-2014-08-26", "https://www.nasdaq.com/articles/sector-update-health-care-2014-08-26-1", "https://www.nasdaq.com/articles/alkermes-gains-on-aripiprazole-lauroxil-nda-submission-analyst-blog-2014-08-26", "https://www.nasdaq.com/articles/thursdays-etf-movers-bbh-gxc-2014-08-14", "https://www.nasdaq.com/articles/alkermes-reports-loss-in-q2-on-higher-costs-revenues-up-analyst-blog-2014-08-04", "https://www.nasdaq.com/articles/biotech-stock-roundup-gileads-sovaldi-biogens-tecfidera-impressive-run-continues-analyst", "https://www.nasdaq.com/articles/first-week-october-18th-options-trading-alkermes-alks-2014-09-08", "https://www.nasdaq.com/articles/alkermes-aripiprazole-lauroxil-looks-promising-analyst-blog-2014-06-19", "https://www.nasdaq.com/articles/sector-update-healthcare-2014-06-18", "https://www.nasdaq.com/articles/sector-update-healthcare-shares-flat-pre-market-pfizer-teams-cellectis-immunotherapy-2014", "https://www.nasdaq.com/articles/alkermes-progresses-with-its-late-stage-candidate-analyst-blog-2014-06-11", "https://www.nasdaq.com/articles/alkermes-pipeline-holds-promise-analyst-blog-2014-06-06", "https://www.nasdaq.com/articles/wider-than-expected-loss-at-alkermes-revenues-slip-analyst-blog-2014-05-01", "https://www.nasdaq.com/articles/alkermes-pipeline-development-impresses-key-updates-ahead-analyst-blog-2014-07-21", "https://www.nasdaq.com/articles/sector-update-healthcare-shares-mixed-pre-market-wellpoint-2-q1-results-2014-04-30", "https://www.nasdaq.com/articles/biotech-stock-roundup-mannkind-pdufa-date-pushed-out-alkermes-impresses-data-analyst-blog", "https://www.nasdaq.com/articles/gilead-sciences-gild-falls%3A-stock-goes-down-7.3-tale-of-the-tape-2014-04-11", "https://www.nasdaq.com/articles/3-top-ranked-biotech-stocks-rebound-analyst-blog-2014-04-10", "https://www.nasdaq.com/articles/halozyme-study-under-clinical-hold-analyst-blog-2014-04-10", "https://www.nasdaq.com/articles/immunogen-up-on-positive-pipeline-data-analyst-blog-2014-04-10", "https://www.nasdaq.com/articles/gilead-announces-encouraging-sovaldi-data-analyst-blog-2014-04-10", "https://www.nasdaq.com/articles/sector-update-healthcare-2014-04-30-1", "https://www.nasdaq.com/articles/positive-trial-data-lifts-alkermes-analyst-blog-2014-04-09", "https://www.nasdaq.com/articles/pharmacyclics-files-snda-analyst-blog-2014-04-09", "https://www.nasdaq.com/articles/oncolytics-reports-additional-data-on-reolysin-analyst-blog-2014-04-09", "https://www.nasdaq.com/articles/ambits-oncology-drug-in-phase-iii-analyst-blog-2014-04-09", "https://www.nasdaq.com/articles/seattle-genetics-earns-milestone-payment-analyst-blog-2014-04-09", "https://www.nasdaq.com/articles/halozyme-falls-on-phase-ii-study-halt-analyst-blog-2014-04-08", "https://www.nasdaq.com/articles/bristol-myers-seeks-fda-approval-for-hcv-candidates-analyst-blog-2014-04-08", "https://www.nasdaq.com/articles/biotech-stock-roundup-mannkind-soars-panel-vote-halozyme-plunges-safety-concerns-analyst", "https://www.nasdaq.com/articles/positive-trial-data-lifts-alkermes-analyst-blog-2014-04-09", "https://www.nasdaq.com/articles/radnet-touches-new-52-week-high-analyst-blog-2014-04-08", "https://www.nasdaq.com/articles/agios-pharmaceuticals-agio-surges%3A-stock-moves-27.8-higher-tale-of-the-tape-2014-04-08", "https://www.nasdaq.com/articles/mannkind-slips-on-afrezza-approval-delay-analyst-blog-2014-04-08", "https://www.nasdaq.com/articles/idenix-pharmaceuticals-idix-jumps%3A-stock-up-12.4-tale-of-the-tape-2014-04-08", "https://www.nasdaq.com/articles/puma-biotechnology-pbyi-in-focus%3A-stock-tumbles-18.3-tale-of-the-tape-2014-04-08", "https://www.nasdaq.com/articles/sector-update-healthcare-shares-higher-pre-market-alkermes-11-phase-3-trial-results-2014", "https://www.nasdaq.com/articles/fda-target-date-for-gileads-hcv-candidate-analyst-blog-2014-04-08", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-mixed-schulman-lifts-profit-outlook-2014-04-08", "https://www.nasdaq.com/articles/radnet-touches-new-52-week-high-analyst-blog-2014-04-08", "https://www.nasdaq.com/articles/agios-pharmaceuticals-agio-surges%3A-stock-moves-27.8-higher-tale-of-the-tape-2014-04-08", "https://www.nasdaq.com/articles/mannkind-slips-on-afrezza-approval-delay-analyst-blog-2014-04-08", "https://www.nasdaq.com/articles/pipeline-update-from-idenix-analyst-blog-2014-04-08", "https://www.nasdaq.com/articles/healthcare-stocks-losing-ground-ahead-closing-bell-alkermes-3-positive-results", "https://www.nasdaq.com/articles/sector-update-healthcare-2014-04-08-1", "https://www.nasdaq.com/articles/mid-afternoon-market-update-markets-recover-slightly-coal-shows-strength-2014-04-08", "https://www.nasdaq.com/articles/mid-day-market-update-us-stocks-gain-gigamon-shares-dip-lower-forecast-2014-04-08", "https://www.nasdaq.com/articles/amgens-oncology-candidate-disappoints-analyst-blog-2014-04-07", "https://www.nasdaq.com/articles/response-genetics-rgdx-in-focus%3A-stock-up-18.3-tale-of-the-tape-2014-04-04", "https://www.nasdaq.com/articles/weakness-seen-in-kindred-biosciences-kin%3A-stock-tumbles-9.0-tale-of-the-tape-2014-04-04", "https://www.nasdaq.com/articles/glaxo-and-amgen-terminate-agreement-analyst-blog-2014-04-04", "https://www.nasdaq.com/articles/acceleron-pharma-xlrn-jumps%3A-stock-up-13.2-tale-of-the-tape-2014-04-03", "https://www.nasdaq.com/articles/sector-update-healthcare-2014-04-08-0", "https://www.nasdaq.com/articles/celladon-cldn-jumps%3A-stock-up-5.9-tale-of-the-tape-2014-04-01", "https://www.nasdaq.com/articles/momenta-pharmaceuticals-slumps%3A-mnta-falls-16.9-in-session-tale-of-the-tape-2014-04-01", "https://www.nasdaq.com/articles/exact-sciences-exas-jumps%3A-stock-adds-10.2-in-session-tale-of-the-tape-2014-04-01", "https://www.nasdaq.com/articles/glaxo-presents-darapladib-data-analyst-blog-2014-03-31", "https://www.nasdaq.com/articles/idera-soars-on-phase-ii-drug-data-analyst-blog-2014-03-31", "https://www.nasdaq.com/articles/alkermes-larger-sp-500-component-joy-global-2014-03-31", "https://www.nasdaq.com/articles/endocyte-prices-new-offering-at-%2421-per-share-analyst-blog-2014-03-31", "https://www.nasdaq.com/articles/encouraging-results-on-gileads-sovaldi-analyst-blog-2014-04-03", "https://www.nasdaq.com/articles/gileads-hcv-candidate-under-review-in-the-eu-analyst-blog-2014-03-28", "https://www.nasdaq.com/articles/insmed-incorporated-saw-its-shares-rise-more-than-7-in-the-session.-tale-of-the-tape-2014", "https://www.nasdaq.com/articles/encouraging-data-on-pfizer-cholesterol-drug-analyst-blog-2014-03-28", "https://www.nasdaq.com/articles/integra-lifesciences-introduces-wound-matrix-analyst-blog-2014-03-28", "https://www.nasdaq.com/articles/cvs-caremark-receives-fep-contract-analyst-blog-2014-03-28", "https://www.nasdaq.com/articles/bbh-alks-bmrn-isis-large-outflows-detected-etf-2014-03-27", "https://www.nasdaq.com/articles/china-cord-blood-corporation-co-soars%3A-stock-up-5.7-tale-of-the-tape-2014-03-27", "https://www.nasdaq.com/articles/fda-nod-for-biogens-alprolix-analyst-blog-2014-03-31", "https://www.nasdaq.com/articles/insmed-down-on-disappointing-arikayce-results-analyst-blog-2014-03-27", "https://www.nasdaq.com/articles/avanirs-avp-825-under-fda-review-analyst-blog-2014-03-27", "https://www.nasdaq.com/articles/positive-data-on-pfizers-genotropin-analyst-blog-2014-03-27", "https://www.nasdaq.com/articles/what-falling-estimates-price-mean-for-kythera-kyth-tale-of-the-tape-2014-03-26", "https://www.nasdaq.com/articles/ucb-to-return-tozadenant-rights-analyst-blog-2014-03-26", "https://www.nasdaq.com/articles/update-on-forest-labs-cariprazine-analyst-blog-2014-03-25", "https://www.nasdaq.com/articles/positive-chmp-opinion-for-novo-nordisks-drugs-analyst-blog-2014-03-25", "https://www.nasdaq.com/articles/exelixis-cometriq-approved-in-the-eu-analyst-blog-2014-03-27", "https://www.nasdaq.com/articles/insmed-down-on-disappointing-arikayce-results-analyst-blog-2014-03-27", "https://www.nasdaq.com/articles/endocyte-surges-on-vynfinit-news-analyst-blog-2014-03-24", "https://www.nasdaq.com/articles/trial-protocol-submission-lifts-heat-biologics-analyst-blog-2014-03-21", "https://www.nasdaq.com/articles/sinovac-biotech-sva-soars%3A-stock-rises-17.1-tale-of-the-tape-2014-03-21", "https://www.nasdaq.com/articles/strength-seen-in-ziopharm-oncology-ziop%3A-stock-up-11.8-tale-of-the-tape-2014-03-21", "https://www.nasdaq.com/articles/oncolytics-biotech-oncy-jumps%3A-stock-rises-5-tale-of-the-tape-2014-03-21", "https://www.nasdaq.com/articles/aveo-pharmaceuticals-aveo-jumps%3A-stock-rises-7.2-tale-of-the-tape-2014-03-24", "https://www.nasdaq.com/articles/glaxos-mage-a3-candidate-disappoints-again-analyst-blog-2014-03-21", "https://www.nasdaq.com/articles/avanir-provides-new-data-analyst-blog-2014-03-21", "https://www.nasdaq.com/articles/good-news-for-johnson-johnson-analyst-blog-2014-03-21", "https://www.nasdaq.com/articles/positive-data-on-novo-nordisks-n8-gp-analyst-blog-2014-03-20", "https://www.nasdaq.com/articles/prothena-prta-jumps%3A-stock-rises-27.5-tale-of-the-tape-2014-03-20", "https://www.nasdaq.com/articles/sequenom-sqnm-soars%3A-stock-rises-6.4-tale-of-the-tape-2014-03-20", "https://www.nasdaq.com/articles/why-ani-pharmaceuticals-anip-has-a-bright-short-term-future-tale-of-the-tape-2014-03-20", "https://www.nasdaq.com/articles/qiagens-quantiferon-tb-test-now-in-china-analyst-blog-2014-03-21", "https://www.nasdaq.com/articles/oncomeds-q4-loss-narrows-analyst-blog-2014-03-20", "https://www.nasdaq.com/articles/intrexon-deal-update-overshadows-q4-loss-at-fibrocell-analyst-blog-2014-03-19", "https://www.nasdaq.com/articles/idenix-files-lawsuit-vs.-gilead-again-analyst-blog-2014-03-19", "https://www.nasdaq.com/articles/novo-nordisk-extends-diabetes-operations-analyst-blog-2014-03-19", "https://www.nasdaq.com/articles/biolinerx-reports-narrower-2013-loss-analyst-blog-2014-03-18", "https://www.nasdaq.com/articles/horizon-pharma-hznp-jumps%3A-stock-rises-5.6-tale-of-the-tape-2014-03-18", "https://www.nasdaq.com/articles/narrower-than-expected-loss-at-relypsa-analyst-blog-2014-03-18", "https://www.nasdaq.com/articles/genomic-health-unveils-oncotype-dx-data-analyst-blog-2014-03-20", "https://www.nasdaq.com/articles/glaxo-theravance-update-on-copd-drugs-analyst-blog-2014-03-18", "https://www.nasdaq.com/articles/repros-provides-proellex-update-analyst-blog-2014-03-18", "https://www.nasdaq.com/articles/pipeline-update-from-biodelivery-sciences-analyst-blog-2014-03-18", "https://www.nasdaq.com/articles/intercept-sees-weakness-in-earnings-result-analyst-blog-2014-03-18", "https://www.nasdaq.com/articles/amgen-scores-again-with-pcsk9-inhibitor-analyst-blog-2014-03-18", "https://www.nasdaq.com/articles/biogen-to-be-added-to-sp100-analyst-blog-2014-03-18", "https://www.nasdaq.com/articles/update-on-glaxos-pipeline-analyst-blog-2014-03-17", "https://www.nasdaq.com/articles/five-prime-therapeutics-fprx-surges%3A-stock-moves-22.6-higher-tale-of-the-tape-2014-03-18", "https://www.nasdaq.com/articles/progenics-q4-loss-narrower-than-expected-analyst-blog-2014-03-14", "https://www.nasdaq.com/articles/revenues-decline-at-discovery-labs-in-q4-shares-down-analyst-blog-2014-03-14", "https://www.nasdaq.com/articles/narrower-than-expected-q4-loss-at-repros-analyst-blog-2014-03-14", "https://www.nasdaq.com/articles/vanda-pharmaceuticals-vnda-soars%3A-stock-adds-9.6-in-session-tale-of-the-tape-2014-03-14", "https://www.nasdaq.com/articles/insmed-insm-looks-good%3A-stock-adds-5.9-in-session-tale-of-the-tape-2014-03-14", "https://www.nasdaq.com/articles/first-laminoplasty-implant-at-integra-analyst-blog-2014-03-14", "https://www.nasdaq.com/articles/astrazeneca-to-sell-cheshire-research-site-analyst-blog-2014-03-13", "https://www.nasdaq.com/articles/raptor-pharma-posts-wider-than-expected-q4-loss-analyst-blog-2014-03-14", "https://www.nasdaq.com/articles/bright-outlook-at-bayer-analyst-blog-2014-03-13", "https://www.nasdaq.com/articles/geron-plunges-on-fda-clinical-hold-analyst-blog-2014-03-13", "https://www.nasdaq.com/articles/glaxo-strengthens-indian-presence-analyst-blog-2014-03-12", "https://www.nasdaq.com/articles/pipeline-update-at-biolinerx-analyst-blog-2014-03-12", "https://www.nasdaq.com/articles/regado-rises-on-reg1-fast-track-designation-analyst-blog-2014-03-11", "https://www.nasdaq.com/articles/alexion-lifts-2014-view-shares-up-analyst-blog-2014-03-11", "https://www.nasdaq.com/articles/biogen-upgraded-to-strong-buy-analyst-blog-2014-03-10", "https://www.nasdaq.com/articles/narrower-loss-at-orexigen-in-q4-analyst-blog-2014-03-13", "https://www.nasdaq.com/articles/emergent-beats-on-earnings-revenues-shares-up-analyst-blog-2014-03-10", "https://www.nasdaq.com/articles/additional-positive-data-on-omeros-treatment-analyst-blog-2014-03-10", "https://www.nasdaq.com/articles/newlink-genetics-shares-sink-analyst-blog-2014-03-10", "https://www.nasdaq.com/articles/why-you-need-to-pay-attention-to-kamada-kmda-stock-tale-of-the-tape-2014-03-07", "https://www.nasdaq.com/articles/alcobra-gains-ind-clearance-for-mdx-analyst-blog-2014-03-07", "https://www.nasdaq.com/articles/pipeline-progress-at-alkermes-analyst-blog-2014-03-07", "https://www.nasdaq.com/articles/rigel-rises-on-narrower-q4-loss-analyst-blog-2014-03-06", "https://www.nasdaq.com/articles/aegerion-pharmaceuticals-aegr-soars%3A-stock-rises-10.6-tale-of-the-tape-2014-03-10", "https://www.nasdaq.com/articles/regulatory-update-on-cubist-pharmas-tedizolid-analyst-blog-2014-03-06", "https://www.nasdaq.com/articles/update-on-alexions-soliris-analyst-blog-2014-03-05", "https://www.nasdaq.com/articles/narrower-than-expected-q4-loss-at-gtx-analyst-blog-2014-03-05", "https://www.nasdaq.com/articles/acorda-therapeutics-acor-jumps%3A-stock-rises-7.5-tale-of-the-tape-2014-03-05", "https://www.nasdaq.com/articles/ovascience-ovas-in-focus%3A-stock-tanks-9.5-analyst-blog-2014-03-05", "https://www.nasdaq.com/articles/narrower-than-expected-loss-at-dendreon-drives-shares-up-analyst-blog-2014-03-04", "https://www.nasdaq.com/articles/celldex-therapeutics-cldx-in-focus%3A-stock-tumbles-10.1-tale-of-the-tape-2014-03-04", "https://www.nasdaq.com/articles/osiris-misses-on-q4-earnings-analyst-blog-2014-03-06", "https://www.nasdaq.com/articles/actelion-gains-on-qidp-and-fast-track-status-analyst-blog-2014-03-03", "https://www.nasdaq.com/articles/update-on-anacors-an2728-analyst-blog-2014-03-03", "https://www.nasdaq.com/articles/earnings-decline-yoy-at-alkermes-analyst-blog-2014-02-28", "https://www.nasdaq.com/articles/medivation-swings-to-earnings-in-q4-analyst-blog-2014-02-28", "https://www.nasdaq.com/articles/zacks-rank-1-additions-for-friday-tale-of-the-tape-2014-02-28", "https://www.nasdaq.com/articles/interesting-alks-put-and-call-options-april-19th-2014-02-25", "https://www.nasdaq.com/articles/isis-pharma-soars-on-positive-data-analyst-blog-2014-02-24", "https://www.nasdaq.com/articles/isis-pharma-slips-on-wider-than-expected-q4-loss-analyst-blog-2014-03-04", "https://www.nasdaq.com/articles/actelion-gains-on-qidp-and-fast-track-status-analyst-blog-2014-03-03", "https://www.nasdaq.com/articles/notice-of-allowance-received-by-alkermes-analyst-blog-2014-01-07", "https://www.nasdaq.com/articles/3-rallying-outperforming-stocks-high-employee-ratings-2014-01-02", "https://www.nasdaq.com/articles/alkermes-plc-alks-new-analyst-report-zacks-equity-research-zacks-equity-research-report", "https://www.nasdaq.com/articles/pharma-biotech-stock-outlook-dec-2013-zacks-analyst-interviews-2013-12-03", "https://www.nasdaq.com/articles/pharma-biotech-stock-outlook-dec-2013-industry-outlook-2013-12-03", "https://www.nasdaq.com/articles/vertex-kalydeco-approved-for-an-additional-indication-analyst-blog-2014-02-24", "https://www.nasdaq.com/articles/strength-seen-in-alkermes-alks%3A-stock-up-8.5-analyst-blog-2013-10-18", "https://www.nasdaq.com/articles/alkermes-alks-5461-encourages-analyst-blog-2013-10-15", "https://www.nasdaq.com/articles/alkermes-pipeline-encourages-analyst-blog-2013-10-14", "https://www.nasdaq.com/articles/pipeline-progress-at-alkermes-analyst-blog-2013-10-09", "https://www.nasdaq.com/articles/update-on-alkermes-portfolio-analyst-blog-2013-10-02", "https://www.nasdaq.com/articles/acorda-progresses-with-pipeline-analyst-blog-2013-09-30", "https://www.nasdaq.com/articles/halozyme-halo-in-focus%3A-stock-rises-6.9-analyst-blog-2013-09-30", "https://www.nasdaq.com/articles/marginal-earnings-miss-at-alkermes-analyst-blog-2013-11-01", "https://www.nasdaq.com/articles/after-hours-most-active-jul-3-2013-siri-qqq-itub-valep-zts-pbr-pbra-wfc-alks-wcrx-znga", "https://www.nasdaq.com/articles/biogen-delays-eu-launch-of-tecfidera-analyst-blog-2013-05-31", "https://www.nasdaq.com/articles/amgen-astellas-collaborate-analyst-blog-2013-05-29", "https://www.nasdaq.com/articles/encouraging-data-from-alkermes-analyst-blog-2013-05-29", "https://www.nasdaq.com/articles/biogen-submits-plegridy-bla-analyst-blog-2013-05-23", "https://www.nasdaq.com/articles/alkermes-reports-earnings-for-q4-analyst-blog-2013-05-23", "https://www.nasdaq.com/articles/pre-market-earnings-report-may-23-2013-td-rl-hrl-dltr-aap-sig-gme-pdco-alks-bke-ttc-ainv", "https://www.nasdaq.com/articles/earnings-beat-at-alkermes-analyst-blog-2013-07-26", "https://www.nasdaq.com/articles/qiagen-downgraded-to-strong-sell-analyst-blog-2013-05-21", "https://www.nasdaq.com/articles/biogens-hemophilia-bla-accepted-analyst-blog-2013-05-20", "https://www.nasdaq.com/articles/sgens-adcetris-under-fda-review-analyst-blog-2013-05-16", "https://www.nasdaq.com/articles/cempra-toyama-ink-deal-analyst-blog-2013-05-15", "https://www.nasdaq.com/articles/much-awaited-test-launch-by-genomic-analyst-blog-2013-05-15", "https://www.nasdaq.com/articles/myriad-soars-higher-on-celeb-clout-analyst-blog-2013-05-15", "https://www.nasdaq.com/articles/isis-gets-%243.5m-milestone-payment-analyst-blog-2013-05-14", "https://www.nasdaq.com/articles/yet-another-acquisition-for-bayer-analyst-blog-2013-05-21", "https://www.nasdaq.com/articles/biomarin-widens-loss-maintains-view-analyst-blog-2013-04-29", "https://www.nasdaq.com/articles/zacks-rank-1-addition-for-tuesday-tale-of-the-tape-2013-04-23", "https://www.nasdaq.com/articles/illumina-beats-on-earnings-revenue-analyst-blog-2013-04-23", "https://www.nasdaq.com/articles/pipeline-progress-at-alkermes-analyst-blog-2013-04-18", "https://www.nasdaq.com/articles/mid-day-market-update-cirrus-logic-plunges-weak-forecast-atlas-energy-rises-2013-04-17", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-move-lower-bank-america-posts-downbeat-q1-profit-2013-04", "https://www.nasdaq.com/articles/market-wrap-wednesday-april-17-stocks-plunge-again-along-euro-2013-04-17", "https://www.nasdaq.com/articles/week-ahead-full-slate-economic-data-earnings-cisco-wal-mart-and-deere-2013-05-10", "https://www.nasdaq.com/articles/biotech-alkermes-poised-swell-pipeline-wins-2013-04-16", "https://www.nasdaq.com/articles/alkermes-announces-restructuring-plan-analyst-blog-2013-04-11", "https://www.nasdaq.com/articles/setback-for-amgen-analyst-blog-2013-02-27", "https://www.nasdaq.com/articles/royalty-pharma-eyes-elan-corp.-analyst-blog-2013-02-26", "https://www.nasdaq.com/articles/elan-updates-future-plans-analyst-blog-2013-02-25", "https://www.nasdaq.com/articles/symmetry-misses-but-up-y-y-analyst-blog-2013-02-22", "https://www.nasdaq.com/articles/biomarin-reports-wider-loss-analyst-blog-2013-02-22", "https://www.nasdaq.com/articles/mid-afternoon-market-update-markets-remain-down-abiomed-rises-2013-04-17", "https://www.nasdaq.com/articles/savient-to-promote-sobis-kineret-analyst-blog-2013-02-21", "https://www.nasdaq.com/articles/celgene-plans-%24600m-share-buyback-analyst-blog-2013-02-21", "https://www.nasdaq.com/articles/aliof-candidate-approved-in-japan-analyst-blog-2013-02-20", "https://www.nasdaq.com/articles/positive-data-from-bmrns-pku-016-analyst-blog-2013-02-20", "https://www.nasdaq.com/articles/amgen-provides-long-term-update-analyst-blog-2013-02-13", "https://www.nasdaq.com/articles/loss-at-mannkind-wider-than-expected-analyst-blog-2013-02-12", "https://www.nasdaq.com/articles/affymetrix-links-up-with-dna-link-analyst-blog-2013-02-11", "https://www.nasdaq.com/articles/zacks-rank-1-addition-for-friday-tale-of-the-tape-2013-02-22", "https://www.nasdaq.com/articles/data-on-biogen-hemophilia-candidates-analyst-blog-2013-02-11", "https://www.nasdaq.com/articles/zacks-rank-1-addition-for-friday-tale-of-the-tape-2013-02-08", "https://www.nasdaq.com/articles/zacks-rank-1-addition-for-wednesday-tale-of-the-tape-2013-02-06", "https://www.nasdaq.com/articles/elan-to-sell-remaining-alks-stake-analyst-blog-2013-02-04", "https://www.nasdaq.com/articles/alkermes-turns-to-profit-ups-view-analyst-blog-2013-02-01", "https://www.nasdaq.com/articles/affymetrixs-4q-eps-in-line-analyst-blog-2013-02-01", "https://www.nasdaq.com/articles/zacks-rank-1-addition-for-wednesday-tale-of-the-tape-2013-01-30", "https://www.nasdaq.com/articles/alkermes-plc-enters-oversold-territory-tale-of-the-tape-2013-02-11", "https://www.nasdaq.com/articles/data-on-biogen-hemophilia-candidates-analyst-blog-2013-02-11", "https://www.nasdaq.com/articles/zacks-1-rank-additions-for-tuesday-tale-of-the-tape-2013-01-15", "https://www.nasdaq.com/articles/alkermes-maintains-fiscal-2013-view-analyst-blog-2013-01-09", "https://www.nasdaq.com/articles/positive-data-on-alkermes-candidate-analyst-blog-2013-01-04", "https://www.nasdaq.com/articles/elan-hives-off-prothena-analyst-blog-2012-12-27", "https://www.nasdaq.com/articles/alkermes-reverts-to-neutral-analyst-blog-2012-11-16", "https://www.nasdaq.com/articles/revenues-rise-at-alkermes-analyst-blog-2012-11-05", "https://www.nasdaq.com/articles/arena-falters-on-belviq-eu-approval-analyst-blog-2013-01-23", "https://www.nasdaq.com/articles/alkermes-upped-to-outperform-analyst-blog-2012-10-12", "https://www.nasdaq.com/articles/get-ready-be-surprised-earnings-season-screen-week-2012-10-02", "https://www.nasdaq.com/articles/alkermes-debt-refinanced-analyst-blog-2012-10-01", "https://www.nasdaq.com/articles/zacks-1-rank-additions-for-friday-tale-of-the-tape-2012-09-28", "https://www.nasdaq.com/articles/back-to-neutral-on-alkermes-analyst-blog-2012-09-18", "https://www.nasdaq.com/articles/alkermes-writes-new-prescription-growth-2012-09-17", "https://www.nasdaq.com/articles/elan-to-split-into-two-companies-analyst-blog-2012-08-14", "https://www.nasdaq.com/articles/alkermes-plc-alks-bull-of-the-day-2012-10-26", "https://www.nasdaq.com/articles/alkermes-plc-enters-oversold-territory-tale-of-the-tape-2012-08-10", "https://www.nasdaq.com/articles/solid-quarter-at-alks-view-backed-analyst-blog-2012-07-31", "https://www.nasdaq.com/articles/pre-market-earnings-report-july-26-2012-mmm-pld-agco-abb-alk-alks-ddd-asps-aciw-aixg-alu", "https://www.nasdaq.com/articles/alkermes-plc-alks-bull-of-the-day-2012-07-11", "https://www.nasdaq.com/articles/alkermes-upped-to-outperform-analyst-blog-2012-07-10", "https://www.nasdaq.com/articles/zacks-1-rank-additions-for-monday-tale-of-the-tape-2012-07-02", "https://www.nasdaq.com/articles/pipeline-progress-at-alkermes-jnj-analyst-blog-2012-06-13", "https://www.nasdaq.com/articles/companys-first-profit-can-mean-big-gains-investors-screen-week-2012-08-14", "https://www.nasdaq.com/articles/best-health-care-investor-edward-owens-buys-one-new-health-care-stock-first-quarter-2012", "https://www.nasdaq.com/articles/elan-sells-76-stake-in-alkermes-analyst-blog-2012-03-16", "https://www.nasdaq.com/articles/risk-reward-balanced-at-alkermes-analyst-blog-2012-03-06", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-charles-schwab-etrade-financial-td-ameritrade-holding", "https://www.nasdaq.com/articles/amylins-bydureon-launches-in-the-us-analyst-blog-2012-02-15", "https://www.nasdaq.com/articles/elans-4q-loss-wider-than-expected-analyst-blog-2012-02-14", "https://www.nasdaq.com/articles/novo-nordisk-posts-solid-4q-analyst-blog-2012-02-06", "https://www.nasdaq.com/articles/revenues-skyrocket-at-merged-alkermes-analyst-blog-2012-05-18", "https://www.nasdaq.com/articles/revenues-skyrocket-at-merged-alkermes-analyst-blog-2012-02-03", "https://www.nasdaq.com/articles/new-study-for-alkermes-vivitrol-analyst-blog-2012-02-01", "https://www.nasdaq.com/articles/zyprexa-pulls-down-lillys-4q-sales-analyst-blog-2012-01-31", "https://www.nasdaq.com/articles/third-time-lucky-for-amylins-bydureon-analyst-blog-2012-01-30", "https://www.nasdaq.com/articles/good-news-for-alkermes-pipeline-analyst-blog-2012-01-05", "https://www.nasdaq.com/articles/pipeline-progress-at-alkermes-analyst-blog-2011-12-21", "https://www.nasdaq.com/articles/pipeline-progress-at-alkermes-analyst-blog-2011-12-21-0", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-alkermes-plc-elan-johnson-johnson-amylin", "https://www.nasdaq.com/articles/update-top-unusual-option-activity-2011-10-03", "https://www.nasdaq.com/articles/mid-day-update-stocks-gain-greece-worries-abate-existing-home-sales-match-street-fall-2011", "https://www.nasdaq.com/articles/stocks-gains-greek-debt-crisis-eases-home-sales-line-fed-meeting-ahead-2011-06-21", "https://www.nasdaq.com/articles/stocks-accelerating-gains-despite-persistent-greek-debt-worries-deal-news-supports-2011-05", "https://www.nasdaq.com/articles/mid-day-update-stocks-getting-lift-deal-news-greece-worries-simmer-2011-05-09", "https://www.nasdaq.com/articles/mid-day-update-stocks-firmer-following-data-deluge-corporate-earnings-2011-04-15", "https://www.nasdaq.com/articles/major-indexes-positive-territory-earnings-season-presses-fed-beige-book-tap-2010-10-20", "https://www.nasdaq.com/articles/greenback-rally-here-are-stocks-stand-benefit-2011-11-15", "https://www.nasdaq.com/articles/alkermes-alks-investor-boosts-call-volume-2010-07-15", "https://www.nasdaq.com/articles/bull-looks-alkermes-bounce-2010-06-09", "https://www.nasdaq.com/articles/alkermes-faces-bearish-strategy-2010-05-17", "https://www.nasdaq.com/articles/bull-extends-position-alkermes-2010-04-19", "https://www.nasdaq.com/articles/mid-day-update-stocks-strong-advance-eyes-ahead-feds-beige-book-2010-10-20"], "Content": []}